Most eczema sufferers are stuck in the same-spot comeback. They treat a flare in a short, frightened burst, usually with a steroid cream, stop the moment the skin looks clear, and watch the flare return in the same place within days or weeks, often angrier than before. After enough rounds they conclude either that the cream is the enemy, because it only works while they use it and comes back worse when they stop, or that the real cause must be inside them, in their diet, gut or immune system. That conclusion keeps them away from the one approach the evidence says breaks the loop, which is steady care of the usual spots on the days they look fine.
Clear skin is not healed skin. For weeks after a flare calms, the spot keeps a weak top layer and a pocket of primed immune cells, which is why the flare comes back in exactly the same place. Looking after those few usual spots on the good days, with daily barrier care and, in mainstream medicine, a light anti-inflammatory twice a week, roughly halves relapse in trials. The steroid-free version that fits Phoilex is the one gentle thing she keeps on the spots that keep coming back, alongside whatever her doctor has her on. Three smaller ahas travel with it: the itch is mostly not histamine, so allergy pills rarely help; food is rarely the cause in adults, and elimination diets help very little; and fear of steroids causes enough under-treatment that frightened patients often end up in bigger rescue bursts.
The first number is eight hundred and thirty-seven of one thousand three hundred and ninety-one, the share of Phoilex purchases in ninety days that came from people aged sixty-five and over, about six in every ten. The second is roughly half, the cut in relapse risk when the usual spots are treated proactively twice a week after a flare clears, with pooled relative risks of about forty-three to forty-six percent. The third is one in four, the share of adults with atopic dermatitis who first developed it as adults, with new cases rising again after fifty. The fourth is twenty-one to eighty-four percent, the range of patients and caregivers with steroid fear across sixteen studies, a fear linked to skipping treatment at rates of forty-nine percent against fourteen. The fifth is two hundred and ninety-nine, the corpus items voicing the fear that a product will make the skin worse, the first or second objection on every one of Phoilex’s doorways.
The first phrase, heard in all four of Phoilex’s sufferer banks about the steroid cream, is that it “comes back worse” whenever the cream runs out. The second, from a TikTok sufferer in the same banks, calls the cream “a band-aid and never a cure.” The third phrase, from comments everywhere including our own ads, is “I’ve tried everything.” The fourth, from a Reddit comment with two hundred and twenty-three upvotes, is the idea that steroids “don’t cure the root cause.” The fifth, found independently in all four banks, is that the itch is “bone deep.” The sixth, the most physical image in the whole corpus, is “bloody sheets,” together with scratching in my sleep. The seventh, repeated five times in Gladskin’s one-star ratings and echoed by the most-clicked question on our product page, is “it made my skin worse.” The eighth, written under our own ads almost word for word, is “not another cream.” The ninth, from the people who hide their skin, is “I’m tired of hiding my skin.” The tenth, the language of the win, is “I never think about my skin.”
Kalp, this course has one job, which is to make you the person in any room who understands eczema better than the people who have it. That sounds like a tall order, because a woman who has had eczema for thirty years has read more about her skin than most general doctors ever will. She knows the names of the creams, the brands of moisturiser, the arguments on Reddit, and the exact feeling of waking up at three in the morning with blood under her fingernails. What she usually does not have is the whole map: why her skin does this, why every fix she has tried worked for a while and then stopped, where exactly she got stuck, and what would move her past that point. This first episode lays out the whole map in one pass, so that every later episode has a place to hang on.
Start with the size of the thing. The National Eczema Association puts the number of Americans with some form of eczema at about thirty-one point six million, roughly one person in ten. That figure covers every kind of eczema, including hand eczema, contact dermatitis and the rest of the family. The narrower diagnosis, atopic dermatitis, is the one this course mostly means when it says eczema. A study using the National Health Interview Survey found atopic dermatitis in seven point six percent of American adults and twelve point seven percent of American children in 2024, which works out to roughly twenty million adults and nine million children. The children’s figure rose significantly between 2021 and 2024, while the adult figure held steady.
The age curve is the second thing to hold in your head, because it explains who actually buys from us. Eczema has two peaks across a lifetime. The first is in infancy, where most cases start before a child turns five. The second arrives later than most people expect. A primary care analysis of nearly four million people in the United Kingdom found that new cases flatten out through the twenties, thirties and forties, and then climb again from the fifties onward. A pooled analysis of twenty-five studies found that about one adult in four with atopic dermatitis first developed it as an adult. So the market has a young end made of parents buying for babies and toddlers, a middle made of lifelong sufferers who never grew out of it, and an older end made of people whose eczema came back in their fifties or sixties, or arrived for the first time.
That older end is where Phoilex’s money comes from today. Over the ninety days to the end of October, the Phoilex ad account recorded one thousand three hundred and ninety-one purchases, and eight hundred and thirty-seven of them came from people aged sixty-five and over, which is six purchases in every ten. The sixty-five-plus group also bought at the lowest cost per purchase in the account, about forty-five dollars, against eighty-three dollars for people aged thirty-five to forty-four. When you picture the buyer, picture a woman in her late sixties with eczema on her shins and hands, or a grandmother reading a long story ad about a grandson who scratches until he bleeds. Keep the twenty-three-year-old TikTok creator in the picture as well, but understand that she is the voice of the market online and the older woman is the wallet.
Ask a sufferer what she wants and she will say clear skin, but our research shows that clear skin is the door to the thing she actually wants. In a study of four large banks of sufferer language collected for Phoilex in October, covering one hundred and thirty-six TikTok sufferers, five long video journeys, about two thousand five hundred comments and twelve hundred Reddit posts, the win people describe again and again is forgetting about their skin. One Reddit poster wrote that “the biggest change is that I never think about my skin,” and called it a gift. Others describe a full night of sleep, short sleeves in summer, taking their clothes off in the morning without dread, and feeling like themselves again.
The want has a sharp edge in the long recovery stories. When the people who went through steroid withdrawal describe the worst of it, they describe a lost ability, never a symptom. One young woman said her mother had to feed her because she could not hold a fork. A father said he showed a hospital nurse his hands and there was no skin left between his fingers. A mother said she lost a year of being a mother to her son. That pattern matters for everything you will do with this market: the deepest want is getting back the ordinary things the skin took away, and the second deepest want is never having to depend on a tube again. One woman described her goal as an empty bathroom counter after growing up with fifteen creams on it.
A typical adult journey runs like this. A dry, itchy patch appears and she buys something at the pharmacy, usually a CeraVe or Aveeno moisturiser and a tube of over-the-counter hydrocortisone, and the combination helps a little. The patch spreads or keeps returning, so she sees a doctor, who prescribes a stronger steroid cream and tells her to use it for a week or two. It clears, she stops, and within days or weeks it is back in the same place. After a few rounds she gets a stronger cream, then perhaps clobetasol, the strongest class there is. Somewhere along this road she reads about topical steroid withdrawal and gets frightened, and she starts looking for the cause somewhere else: her diet, her gut, her detergent, her water, her stress. She cuts dairy and gluten, takes probiotics and vitamin D, tries tallow or castor oil, and some of it helps at the edges. Then she arrives at one of three places. She goes up the ladder to a biologic injection like Dupixent, or she quits steroids entirely and goes through withdrawal, or she settles into the belief that eczema is a lifelong disease she will manage forever. Episode four walks this road step by step, with separate tracks for parents, adults, the people deep in steroid fear, and the older adults who are our core buyers.
Every market has a place where most people stop moving. In eczema, that place is what this course calls the same-spot comeback. The cream clears the patch, she stops using it the moment the skin looks normal, and the patch returns in the same spot, often angrier than before. She does this five, ten, twenty times. Each return teaches her one of two lessons. Either the cream is the problem, because it only works while she uses it and things come back worse when she stops, or the real cause must be inside her, because nothing on the surface ever lasts. Both lessons feel like hard-won wisdom, and both keep her stuck.
The evidence for this valley is strong in our own research. When Phoilex studied four separate banks of sufferer language, the single most repeated story, present in all four, was the steroid arc in four beats: it works at first, it stops working or needs to be stronger, it comes back worse when you stop, and it thins the skin. The most upvoted line in our Reddit pull of one thousand seven hundred and sixty-nine items is a comment with two hundred and twenty-three upvotes saying that nobody claims steroids do not work, they just do not cure the root cause. Google’s autocomplete for the drops research surfaced eighty-five separate suggestions built around eczema coming back after stopping steroid cream, or coming back in the same spot. Episode five is entirely about this valley, with the counts and the file names.
The counterintuitive truth that moves people out of the valley is that skin which looks clear has not finished healing. Under the calm surface, the skin that just flared still has a weak top layer and still holds immune cells primed to react, and those cells sit in the exact spot that flared before. That is why the flare returns in the same place. The comeback is the old flare finishing on its own schedule, because the quiet skin underneath was never looked after. The fix that the evidence supports is boring and almost nobody does it: keep treating the spots that usually flare, a couple of times a week, while they look fine, and keep the skin’s top layer supplied every day. In trials, that kind of maintenance cuts the chance of a relapse roughly in half.
Here is the honest tension you will meet again and again in this course. Mainstream dermatology does this maintenance with steroid creams or other anti-inflammatory creams, applied twice a week to the usual spots. A large part of the market is afraid of steroids, and Phoilex’s own lead philosophy names the steroid cream as the villain. The bridge between those positions is narrower than either side admits, and it runs through the same principle: the spot that keeps coming back needs attention on the days it looks fine. The people in our research who recovered from steroid withdrawal and stayed well almost all kept one thing, applied only to the worst patches. Phoilex sells a spot gel. Episode six explains how these pieces fit, and where the brand’s philosophies are science and where they are marketing frames.
There are three smaller ahas you will meet as well. The itch of eczema is mostly not driven by histamine, which is why Benadryl and Zyrtec rarely touch it. Food is rarely the cause of eczema in adults, and strict elimination diets help very little while carrying real risks for children. And the fear of steroids, while built on real cases of harm, causes enough under-treatment that the frightened patient often ends up using more steroid in total, in bigger, more desperate bursts.
Phoilex’s research team has organised this market into three levels, and the vocabulary will help you read every other document in the folder. The top level is the doorway, meaning the word she types or the problem she names first. Phoilex’s market map lists eight doorways. The trunk is the steroid door, with typed phrases like steroid free eczema cream and steroid cream rebound, and it carries almost all of the account’s traffic today. The others are hands, face and eyelids, babies and children, Dupixent and the biologics, topical steroid withdrawal, psoriasis, and pregnancy.
The second level is the sub-avatar, meaning the same doorway reached from a different life. On the steroid door, the default reader is the lifelong sufferer, but the same door also holds the woman hiding the crook of her elbow under long sleeves in July, the woman whose eczema came back at forty-seven, and the teenager. On the hands door, the clearest life is the nurse who washes her hands forty times a shift.
The third level is the objection, the reason she has not bought yet. The biggest objection in the whole corpus is the fear that a product will make her skin worse, found in two hundred and ninety-nine items, and it ranks first or second on every doorway. The second biggest is the diet and gut belief, in three hundred and eighty-seven items. Then come cost, the night itch, having tried everything, the conviction that treatments only manage the disease, the experience of something that worked and then stopped, and the feeling of never being taken seriously by doctors.
This is a market in a high emotional state that makes slow, careful decisions. Sufferers are exhausted, often sleep-deprived, frequently ashamed of how their skin looks, and they have been let down many times. At the same time they compare everything, read ingredient lists, and argue with each other in forums. Phoilex’s brief describes the buyer as solution-aware and highly sophisticated, which in Eugene Schwartz’s terms means the market has heard every claim many times and only a genuinely new mechanism or a new way of seeing the problem will get attention.
Skepticism is the default. In the three hundred and eighty-six comments left on Phoilex’s own ads between August and the end of September, nineteen accuse the ads of being fake, AI-written or a scam, and several ask whether anyone at the company is real. One commenter wrote that she was sick to death of ads that all end the same way, with the same prices and the same discounts. Another wrote that the bottom line for her was definitely not another cream or a miracle probiotic. You are selling into a room that has been sold to many times.
You will get the full biology in episode two, but here is the compressed version, the way you would say it to a dermatologist. Atopic dermatitis is a chronic, relapsing inflammatory skin disease built on two failures that feed each other. The first is a weak skin barrier: the outermost layer is short on the proteins and fats that hold water in and keep irritants, allergens and bacteria out, and in a large minority of patients this is inherited through faults in a gene called filaggrin. The second is an immune system tilted toward what immunologists call type two inflammation, driven by messenger molecules called interleukin four, interleukin thirteen and interleukin thirty-one. Those messengers do three things at once: they inflame the skin, they weaken the barrier further, and they talk directly to itch nerves. Staphylococcus aureus bacteria overgrow on the inflamed skin and make it worse. Scratching tears the barrier and keeps the cycle going. Flares come and go because the skin and immune system swing between a quiet, half-healed state and an active one, pushed by triggers such as dry air, sweat, stress, irritants and infection.
The treatment landscape has more options now than at any point in history. Beyond moisturisers and steroid creams, there are non-steroid prescription creams such as tacrolimus, pimecrolimus, crisaborole, ruxolitinib, roflumilast and tapinarof, several of which were approved in the last few years. There are injectable biologics, starting with Dupixent in 2017 and joined since by Adbry, Ebglyss and Nemluvio, and there are daily pills called JAK inhibitors, Rinvoq and Cibinqo, which carry boxed warnings. Dupixent’s list price was about four thousand one hundred and ninety-three dollars per carton of two injections in January 2026, which comes to roughly fifty thousand dollars a year at list price. Episode three is the medicine cabinet, explained one shelf at a time.
Around the medicine sits a large natural and direct-response market. A tallow and honey balm from Terra Lotus has sold more than six hundred and fifty thousand units on TikTok Shop. Emuaid’s emu oil ointment ran an eczema ad for six hundred and nine days that gathered more than one hundred and twenty-eight thousand engagements. Smiles And Joys has been running ads for a steroid-free herbal eczema cream since August 2021. Shower filters, gut supplements and manuka creams all sell to the same woman. The most durable pitch in the category, run for years by several of these sellers, is a natural cream that works without the steroid. Episode nine maps these competitors and what is still open.
Phoilex sells two products into this market. The first is the Active ReLeaf Spot Gel, a steroid-free gel containing ceramides, cholesterol, colloidal oatmeal, vitamin D3 forms, skullcap, bisabolol and a long list of botanicals, sold at forty-two dollars a tube with bundles at seventy-nine and one hundred and twelve. The second is the Liverty Dynamic Drops, an oral herbal oil built around licorice root, milk thistle and lemon balm, which also carries full-spectrum CBD on its label, a fact with real advertising consequences. The brand holds a National Psoriasis Foundation Seal of Recognition for both products, a 2025 SHAPE Skin Award, placement at Ulta, and a mention in a New York Post feature on steroid withdrawal.
The brand has three philosophies in its documents. The first says the steroid cream is the hidden villain that keeps restarting the flares. The second says eczema skin is born short on the fats that hold it together, and the fix is to put those fats back. The third, used for the drops, says the reason it keeps coming back sits inside the body, in stress, sleep and the way the body handles its own cortisol. Episode six and episode ten take each of these apart and sort the science from the marketing frame, because, as you put it, a frame is judged on whether the buyer acts and science is judged on whether it is true.
If you remember nothing else from this hour, remember five things. First, eczema is common and has two age peaks, and Phoilex’s buyers sit mostly in the second, older peak. Second, the deepest want is to forget about the skin and get back the ordinary things it took, plus independence from tubes and routines. Third, the valley is the same-spot comeback, and the belief it creates is that the cream is the enemy or that the cause must be inside. Fourth, the aha is that clear skin is not yet healed skin, and the spot that keeps returning needs attention on the days it looks fine. Fifth, this market has been sold to so many times that it trusts nothing, so whatever you say has to be checkable on the buyer’s own skin.
The rest of the course builds each of these out. Episode two is the body from first principles. Episode three is every treatment on the shelf. Episode four is the journey. Episode five is the valley in detail. Episode six is the aha and how Phoilex’s philosophies sit against the science. Episode seven is myths versus truth. Episode eight is the buyers in their own words. Episode nine is the competitors. Episode ten is the brand itself, with what is true, what is claimable, and where the risks are.
This episode teaches the biology of eczema well enough that you could sit across from a dermatologist and follow every word, and well enough that you can tell when a competitor’s ad, or one of our own documents, has bent the science. We will go from the outside of the skin inward, then into the immune system, then into the itch, and then into the question every sufferer asks, which is why the disease comes and goes. Each section ends with the plain sentence you would use with a buyer, because knowing the mechanism is only half the job and saying it in her words is the other half.
The outermost layer of skin is called the stratum corneum, and it is thinner than a sheet of paper. It is made of flattened dead cells called corneocytes, stacked fifteen to twenty deep, with a waxy mixture of fats packed into the spaces between them. Dermatologists teach this with a picture of bricks and mortar, where the cells are the bricks and the fats are the mortar. The fat mixture is roughly half ceramides by weight, about a quarter cholesterol, and the rest free fatty acids, arranged in tight sheets that water cannot easily cross. The skin’s barrier function lives almost entirely in this thin layer.
The barrier does two jobs. It keeps water in, so the living skin underneath stays supple, and it keeps the outside world out, meaning soaps, detergents, pollen, dust mite droppings, food proteins on the hands and bacteria. When the barrier fails, both jobs fail together. Water escapes faster, which dermatologists measure as transepidermal water loss, and things from outside get in more easily, where they meet the immune cells that live in the skin. This weak barrier is the first half of eczema.
The most important single discovery in eczema research in the last twenty years came in 2006, when a group led by Irwin McLean in Dundee, with Colin Palmer as first author, published in Nature Genetics that loss-of-function mutations in a gene called filaggrin were a major risk factor for atopic dermatitis. Filaggrin is a protein that helps collapse and flatten the skin cells as they move upward, so they stack neatly, and when it breaks down it turns into a set of small molecules called natural moisturising factor, which hold water inside the cells and help keep the skin surface slightly acidic. People who carry a broken copy of the filaggrin gene build a top layer that holds water poorly, sits at a higher pH, and lets things through.
These mutations remain the strongest known genetic risk factor for eczema, and they also predispose people to asthma, hay fever and peanut allergy, which is part of why these conditions travel together in families. They are common in Europeans, carried by somewhere around seven to ten percent of the general population of northern Europe, and in some northern European eczema cohorts they turn up in a quarter to half of patients. They are much rarer in many African and Asian populations, where other barrier genes seem to matter more. So the honest picture has three parts: filaggrin faults are the clearest proof that eczema can start from the barrier, they explain a large share of cases in people of European descent, and most people with eczema worldwide do not carry one. Keep this in mind when any copy, including ours, tells every reader that she was born with a broken barrier.
Eczema skin is also short on ceramides, and that part holds across ethnic groups. Measurements of eczema skin repeatedly show lower total ceramides and a shift toward shorter-chain ceramides that pack less tightly, and the shortage shows up even in skin that looks normal. Part of the reason is inflammation itself, which we come to next.
When you explain this to a buyer, the plain sentence is that her skin’s top layer runs low on the natural oils it uses to hold water in and keep everyday things out, so water leaks out, things get in, and the skin reacts.
The second half of eczema is the immune system. Immunologists divide the body’s inflammatory responses into types. Type one is the response tuned to viruses and bacteria inside cells. Type three handles certain bacteria and fungi on surfaces. Type two evolved to deal with parasites like worms and is the response behind allergies and asthma. Atopic dermatitis is, at its core, a skin disease of type two inflammation, especially in its early and acute phases, with type twenty-two and some type one activity layered on as it becomes chronic.
The key messengers have names you will see on drug labels. Interleukin four and interleukin thirteen are the central type two signals. Interleukin thirty-one is the itch signal. Thymic stromal lymphopoietin, usually shortened to TSLP, and interleukin thirty-three are alarm molecules that stressed or scratched skin cells release to call the immune system in. Dupixent blocks the shared receptor for interleukin four and thirteen. Adbry and Ebglyss block interleukin thirteen. Nemluvio blocks the receptor for interleukin thirty-one. The JAK inhibitor pills and creams block the machinery inside cells that many of these messengers use to pass their signal on. Every modern eczema drug is aimed at some part of this chain.
Here is the part that makes eczema a loop. Interleukin four and thirteen do more than inflame the skin. Laboratory work has shown that they switch down the production of filaggrin, loricrin and other barrier proteins, and they change the way skin cells make ceramides, shifting them toward the shorter, leakier kinds. So a weak barrier lets irritants in, which wakes the immune system, and the immune response then weakens the barrier further. Dermatologists used to argue about which came first, a debate they called outside-in versus inside-out. The current view is that both directions are real and they feed each other. In infants with filaggrin faults the barrier often goes first. In adult-onset eczema, the immune side often seems to lead.
The third player is Staphylococcus aureus, a common bacterium that lives harmlessly in many people’s noses. On eczema skin it overgrows. Studies report it on the majority of lesional eczema skin, around eight in ten patients in some cohorts, and on more than half of non-lesional skin in the same people, against a small fraction of healthy controls. A landmark 2012 study by Heidi Kong and Julie Segre at the National Institutes of Health sequenced the skin bacteria of eleven children with moderate to severe eczema over time and found that the share of Staphylococcus, especially aureus, rose during flares and fell after treatment, and that the share tracked how bad the disease was. In the more severe children a single strain tended to take over during a flare.
Staph aureus makes things worse in several ways. It releases toxins that trigger mast cells, enzymes that break down the skin’s top layer, and proteins called superantigens that switch on large numbers of immune cells at once. Inflamed skin, for its part, makes fewer of its own antimicrobial peptides, which helps the staph thrive. This is the scientific basis for two things you will see in the market: the dilute bleach bath, which aims to cut bacterial load, and the competitor pitch from Emuaid and Sven’s Island that eczema itch keeps returning because of bacteria. The bacterial story is real biology. Whether a given cream fixes it is a separate question that needs its own evidence.
Itch is the symptom sufferers rank as the worst, and it is the one most misunderstood. Most people think of itch as a histamine problem, because a mosquito bite or a hive itches through histamine released by mast cells, and antihistamines like Benadryl and Zyrtec block it. Eczema itch mostly runs on different wiring. A 2017 paper in the journal Cell by Landon Oetjen and Brian Kim showed that sensory nerves in the skin carry receptors for interleukin four, thirteen and thirty-one, so the same immune messengers that drive the rash talk directly to the itch nerves and make them more sensitive. Mice whose nerves lacked the interleukin four receptor scratched far less in an eczema model. Later work found that these messengers sensitise human sensory nerves to many itch triggers at once.
The practical consequence is large. Antihistamines do little for the itch of eczema, and both the American Academy of Dermatology’s 2023 guideline and the allergy societies’ guideline recommend against using them as eczema treatment, leaving a role only for the sedating kind to help a patient sleep. When a buyer tells you she takes Benadryl every night and still scratches, she is describing exactly what the science predicts. On the other side, drugs that block interleukin thirty-one or the interleukin four receptor tend to calm the itch within days, often before the rash looks much better, which patients notice and talk about.
The itch also changes the nerves over time. In chronic eczema, nerve fibres grow up into the outer skin, and the skin develops what researchers call alloknesis, where a light touch, a shirt seam or a change in temperature registers as itch. That is why sufferers describe the itch as “bone deep,” a phrase that turned up independently in all four of Phoilex’s sufferer language banks. It feels like it comes from underneath because, in a sense, the alarm system itself has been turned up.
Scratching relieves itch for a moment by sending pain signals that briefly override it, and the relief is genuinely pleasurable, which is part of why people cannot stop. The cost is that scratching tears the barrier, lets more irritants and bacteria in, releases more alarm molecules from damaged skin cells, and brings more inflammation, which brings more itch. Over months, repeated scratching and rubbing thickens the skin into leathery plaques with exaggerated lines, called lichenification, which itch on their own. Dermatologists call this the itch-scratch cycle, and every competitor in the market names it, including Emuaid in the headline of its eczema page. The cycle is real and is one of the main reasons eczema persists, but naming it is no longer news to this buyer.
Itch gets worse at night for several reasons that stack together. The body’s own cortisol, which suppresses inflammation, is at its lowest in the late evening and early night. Skin temperature rises as the body prepares for sleep, and warmth increases itch. Water loss through the skin is higher at night. And at night there is nothing else to pay attention to. A cross-sectional study of two hundred and forty-one adults with atopic dermatitis confirmed a daily rhythm to the itch, with the evening and night worst. Pooled studies put sleep disturbance in roughly half to four in five children with eczema and a third to nine in ten adults, depending on how it is measured.
This is the biology behind the most powerful image in our corpus, the bloody sheets. People scratch in their sleep without knowing it and wake up to blood on the bedding. One Reddit poster wrote that her bedsheets often looked like a crime scene. A commenter on one of our own ads listed what ten years of eczema had cost him as “itch, sores, bloody sheets, and mental anguish.” When a parent says her child scratches in his sleep, she is describing the circadian rhythm of type two inflammation, and she is also describing the reason she is exhausted.
This section answers the central question of the whole episode. Eczema relapses and remits, meaning it flares up, calms down, and flares again. Sufferers experience this as random, and the market fills that randomness with theories about food, stress and hidden causes. The science gives a more useful answer in three parts.
The first part is that skin which looks clear after a flare is not back to normal. Studies of non-lesional eczema skin, meaning skin that looks fine to the eye, find a weaker barrier, higher water loss, abnormal immune markers and more staph than healthy skin. After a flare is treated, the redness and itch go first, and the deeper abnormalities take weeks longer to settle. Some researchers call this minimal persistent inflammation. It is why a patch that looks healed after five days of steroid cream can flare again a week after the cream stops.
The second part explains why the comeback happens in the same spot. Immunologists have found that after an inflammatory skin disease clears, a population of immune cells called tissue-resident memory T cells stays behind in the skin at the site of the old lesion. These cells remember what they were doing and can restart the inflammation quickly when provoked. This work is most developed in psoriasis, where it explains why plaques return in the same places, and growing evidence points the same way in eczema. Combined with the leftover barrier weakness, it explains the experience sufferers describe in their own words: it always comes back in the same place.
The third part is triggers. A flare usually needs a push, and the pushes are ordinary: dry winter air, overheating and sweat, wool and rough fabrics, harsh soaps, hot showers, a cold, a staph overgrowth, hormonal change, and stress. Stress deserves a special mention because sufferers rank it high. A 2020 National Eczema Society survey in the United Kingdom found that stress was the single most commonly reported trigger, named by fifty-seven percent of women and forty-one percent of men. A 2026 study in the journal Science from Fudan University showed, in mice, that psychological stress activates a set of sympathetic nerves running into the skin that draw a type of immune cell called eosinophils in and worsen dermatitis. For some people, specific allergens such as dust mite or pet dander also play a part, and in a minority of young children, foods can.
Put the three parts together and you get the model this course will use from here on. Eczema skin sits between a quiet, half-healed state and an active state. The half-healed skin is primed to react, especially at old sites. Ordinary triggers push it over the edge. If the quiet state is looked after, through barrier care and, in mainstream medicine, a little anti-inflammatory treatment at the usual sites, the skin is less primed and the same triggers push it over the edge less often. If the quiet state is ignored, the next flare is only a matter of time and trigger.
Eczema often comes first in a sequence that doctors call the atopic march: eczema in infancy, then food allergy, then asthma and hay fever later in childhood. Not every child follows it, and the sequence is better understood as a tendency than a law. The explanation that has gained ground is the dual-allergen exposure hypothesis, proposed by Gideon Lack. It says that when food proteins such as peanut meet the immune system through broken, inflamed skin, the body learns to treat them as threats, while eating the same foods early teaches the body to tolerate them. The LEAP trial, published in 2015, tested this by feeding peanut early to high-risk infants, many of whom had severe eczema, and cut peanut allergy by roughly four-fifths compared with avoidance.
This matters to our market in two ways. It is part of why parents panic, because eczema in a baby can signal food allergy risk. And it inverts a popular belief: the skin, more than the diet, is often the route by which food allergy starts, which is one reason allergy guidelines now recommend against elimination diets for eczema and in favour of early introduction of common allergens for most infants.
Two clinical pictures matter for Phoilex because of who buys. The first is childhood-onset eczema that never left, typically in the creases of the elbows and knees, the neck, hands and face, and in adults often heavier on the hands, eyelids and neck. These buyers have long histories, many treatments behind them, and often the longest steroid exposure.
The second is eczema in older adults. Clinicians now describe atopic dermatitis after sixty as its own variant, more often on the trunk and the outer surfaces of the limbs, with lower blood levels of the allergy antibody IgE than in younger patients, and frequently layered on top of the dry, thin skin that comes with age. Older skin makes less of its own lipids, repairs more slowly, and is more easily thinned by potent steroid creams, so the fear of skin thinning is more than an internet rumour for a seventy-year-old. Older adults also take more medications and have more conditions that complicate treatment, and no randomised trial of Dupixent has been run in people over sixty alone. Our largest group of buyers lives in this picture.
Eczema looks different on darker skin, and mistakes here cost money and trust. Redness, the main sign doctors look for, often appears grey, brown or violet on dark skin, so severity is routinely underestimated, and the standard scoring tools under-rate disease in darker patients. Eczema in Black patients more often shows as small bumps around hair follicles and as thick, lichenified plaques. After a flare, the skin often darkens or lightens for months, called post-inflammatory hyperpigmentation or hypopigmentation, which patients can find as distressing as the rash and which doctors sometimes mistake for active disease. American data suggest Black children are close to twice as likely as white children to develop atopic dermatitis after adjusting for income. The questions about dark marks after a flare on Phoilex’s product page come from this experience.
If you sat with a dermatologist and summarised this episode, you could say something like the following. Atopic dermatitis is a relapsing type two inflammatory disease of the skin built on barrier dysfunction, partly inherited through filaggrin and other barrier genes and partly caused by the inflammation itself, which suppresses barrier proteins and shifts ceramide profiles. Staphylococcus aureus dysbiosis amplifies it, and the itch is largely non-histaminergic, driven by interleukin thirty-one and by interleukin four and thirteen acting on sensory neurons. Clinically clear skin retains barrier defects and resident memory T cells at old sites, which explains same-site relapse, and that is the rationale for proactive maintenance. A dermatologist would nod at every clause.
And if you said it to a buyer, you would say that her skin runs low on the natural oils that hold it together, so things get in and her body fights them, and that fight itself wears the skin down further and sets off an itch that comes from the nerves, which is why the allergy pills never touched it. You would add that when a patch looks clear it is still healing underneath for weeks, which is why it keeps coming back in the same place, and that looking after that spot on the good days is what breaks the pattern. Episode three turns to the treatments, one shelf at a time, with what each one does to this biology.
A sufferer with ten years of eczema has a drawer full of half-used tubes, and every one of them is a story about something that helped for a while. This episode walks through that drawer shelf by shelf, from the moisturiser to the fifty-thousand-dollar injection, and for each shelf it covers what the treatment does to the biology from episode two, what the guidelines say, what it costs, and what the buyer believes about it. Two guideline documents anchor the episode. The first is the American Academy of Dermatology’s 2023 guideline on topical treatment of adults, led by Robert Sidbury, which received a focused update in 2025. The second is the 2023 guideline from the joint task force of the two big American allergy societies, the AAAAI and the ACAAI, led by Derek Chu and published in December 2023 in the Annals of Allergy, Asthma and Immunology. When you hear the phrase “the guidelines” in this course, it means these two.
Moisturisers are the foundation of every eczema plan, and they come in three working types. Humectants such as glycerin and urea pull water into the skin. Occlusives such as petrolatum, the main ingredient in Vaseline and Aquaphor, sit on top and slow water loss. Emollients such as plant oils and fatty alcohols fill the gaps between skin cells and soften. Most products mix all three. The ceramide creams that dominate pharmacy shelves, CeraVe being the biggest, add ceramides on top of this base, and a smaller group of products uses what researchers call a physiological lipid mixture, with ceramides, cholesterol and free fatty acids in roughly the proportions found in healthy skin.
The evidence for moisturisers in established eczema is solid. A Cochrane analysis published in 2017 by Esther van Zuuren and colleagues pooled dozens of trials and found that moisturisers lengthened the time to the next flare, reduced the number of flares and reduced the amount of steroid cream people needed. That same analysis did not find that any one moisturiser clearly beat the others. Ceramide-dominant creams make good biological sense, and some small trials are encouraging, but the evidence that they outperform a plain, well-made moisturiser is thin. That matters for Phoilex, whose second philosophy rests on putting ceramides back.
The guidelines give moisturisers a strong recommendation for adults. The two big prevention trials, BEEP in the United Kingdom with one thousand three hundred and ninety-four high-risk newborns and PreventADALL in Norway and Sweden with two thousand three hundred and ninety-seven, both found that daily moisturiser from birth did not prevent eczema, and BEEP found a small rise in skin infections. So moisturisers treat and stabilise eczema without preventing it, and a better barrier is necessary without being sufficient on its own.
The buyer’s relationship with this shelf is complicated. She has bought many of these products, she believes they only manage the disease, and in our competitor research the tallow sellers have built an entire villain out of the crowded bathroom counter. A small number of people in the steroid withdrawal community go further and stop moisturising altogether, a practice called moisture withdrawal or no moisture treatment, and one young woman in our long video corpus said she thought she had developed “moisturiser addiction.” Phoilex’s villain inventory counted one thousand eight hundred and ninety-two mentions of moisturising in the corpus, the most of any practice.
Topical corticosteroids, usually just called steroid creams, are synthetic versions of cortisol, the body’s own anti-inflammatory hormone. They work by entering skin cells and switching down the production of inflammatory messengers, and they are fast and effective. In the United States they are graded into seven potency classes, from class seven, the weakest, which includes over-the-counter hydrocortisone at one percent, up to class one, the superpotent group, which includes clobetasol propionate. Between them sit the workhorses such as triamcinolone at one tenth of a percent. The strongest classes are hundreds of times more potent than hydrocortisone by the standard skin-blanching test. Ointments are generally stronger than creams of the same drug, and the thin skin of the face, eyelids, armpits and groin absorbs far more, so doctors use the weakest classes there.
The standard dose unit is the fingertip unit, the amount squeezed from a standard tube along the last joint of an adult’s index finger, which is about half a gram and covers an area the size of two adult palms. Many patients use far less than this because they have been told to use it sparingly, and under-dosing is one of the quiet reasons treatment fails.
The guidelines recommend topical steroids strongly. The allergy societies’ guideline suggests applying mid to high potency steroids once a day for flares rather than twice, and strongly recommends maintenance treatment, which means continuing a low or mid-potency steroid, or a calcineurin inhibitor, on the usual sites a couple of times a week after the flare clears. This maintenance approach is called proactive or weekend therapy, and it is the single most important idea in this episode for understanding the valley in episode five. In a 2003 trial in the British Medical Journal by John Berth-Jones and colleagues, three hundred and seventy-six patients were treated to clearance, and those who then used fluticasone twice a week stayed flare-free for more than sixteen weeks on average, against about six weeks for those on moisturiser alone. A 2011 meta-analysis by Jochen Schmitt found that proactive fluticasone cut the relative risk of relapse to about forty-six percent of the comparison, meaning roughly half the flares, and later pooled analyses landed in the same place.
The side effects are real and well described. With repeated use of potent steroids on the same skin, especially thin skin, the skin can thin, a change called atrophy, with fine wrinkling dermatologists describe as cigarette paper, visible small blood vessels, easy bruising, and stretch marks, which are permanent. Mild thinning usually reverses in weeks after stopping. A 1995 study by Haapasaari found that a potent steroid applied twice a day for one week cut collagen production in healthy volunteers’ skin by about two thirds. A Danish registry study of more than seven hundred thousand adults, published by Alexander Egeberg in JAMA Dermatology in 2021, found a small dose-related rise in osteoporosis and fracture risk with very high cumulative use of potent steroid creams. Steroids on the face can cause perioral dermatitis and a rosacea-like rash. Systemic absorption enough to affect the body’s own hormone axis is uncommon and mostly seen with large areas, potent agents, occlusion or young children.
Then there is topical steroid withdrawal, which episode four covers in depth. In short, some people who stop after long, frequent use of moderate to potent steroids develop a severe reaction of burning, spreading redness, peeling and heat that differs from their original eczema. The British medicines regulator acknowledged it in a formal evidence assessment in 2021, and its frequency is still unknown.
The buyer’s relationship with this shelf is the core of our market. Steroid fear, which the literature calls corticophobia, is widespread. A 2017 systematic analysis in JAMA Dermatology by Albert Li and colleagues found it in anywhere from twenty-one to almost eighty-four percent of patients and caregivers across sixteen studies, and where adherence was measured, the fearful were far more likely to skip treatment, forty-nine percent against fourteen percent in one study. Google’s autocomplete shows the fear as its own vocabulary: should I stop using steroid cream, steroid cream thinning skin, steroid cream addiction, steroid cream rebound. Phoilex’s search pull counted four hundred and sixteen strings in that cluster out of two thousand nine hundred and seventy-three.
The first non-steroid prescription creams for eczema were the topical calcineurin inhibitors: tacrolimus ointment, sold as Protopic and approved in 2000, and pimecrolimus cream, sold as Elidel and approved in 2001. They calm the immune response through a different route from steroids, they do not thin the skin, and they are especially useful on the face and eyelids. They often burn or sting for the first several days. In 2006 the FDA added a boxed warning about a theoretical cancer risk, based on animal studies and rare case reports, and later long-term monitoring of children has not shown a clear increase in cancer. That warning is printed on the box, and Phoilex’s villain inventory counted six hundred and twenty-three mentions of these drugs, many of them from people who were handed the cream as the safe alternative to steroids and then read the label.
The next wave arrived in the last decade. Crisaborole, sold as Eucrisa from 2016, blocks an enzyme called phosphodiesterase four, is gentle, and is modestly effective, with stinging a common complaint. Ruxolitinib cream, sold as Opzelura, is a topical JAK inhibitor approved in 2021 for people twelve and over and extended to children from two years old in September 2025, it works quickly on itch, and it carries the class boxed warning for JAK inhibitors with limits on how much can be used. Roflumilast cream at fifteen hundredths of a percent, sold as Zoryve, another phosphodiesterase four blocker, was approved for eczema in July 2024 for ages six and up. Tapinarof cream, sold as Vtama, which works through a receptor called the aryl hydrocarbon receptor, was approved for eczema in December 2024 for ages two and up. For chronic hand eczema specifically, delgocitinib cream, sold as Anzupgo, was approved in July 2025. The 2023 Academy guideline gives strong recommendations to calcineurin inhibitors, phosphodiesterase four inhibitors and topical JAK inhibitors.
These creams matter for you in two ways. First, steroid-free has stopped being unusual even inside the pharmacy, which is part of why our research says that the phrase steroid-free is table stakes. Second, many of these products are expensive and often require insurance approval, which keeps many patients cycling between steroids and over-the-counter products anyway.
Dilute bleach baths, about half a cup of ordinary household bleach in a full bathtub of water, aim to reduce staph on the skin. The allergy societies’ guideline suggests them as an add-on for moderate to severe eczema and suggests against them for mild disease. Pooled studies find that bleach baths reduce severity, and some find plain water baths do nearly as well, so the effect may come partly from the soaking itself. The Academy guideline gives a conditional recommendation against topical antimicrobials and antiseptics in general when there is no clear infection. Phoilex’s corpus counted two hundred and two mentions of bleach baths, and several parents in our own ad comments list them among the many things they tried. Wet wraps, where a damp layer of clothing or bandage goes over moisturiser or steroid, are an intensive treatment for severe flares, often in children, and parents describe them as exhausting nightly work.
Antihistamines are the most common thing sufferers take for itch and among the least useful. As episode two explained, eczema itch is mostly not driven by histamine. The Academy guideline gives a conditional recommendation against using antihistamines to treat eczema, and the allergy guideline agrees, with the sedating kind sometimes used briefly for sleep. Benadryl’s anti-itch gel still sells forty to fifty thousand units a month on Amazon by third-party estimates. The corpus holds three hundred and seventy mentions of antihistamines, and many of them come from people who take one every night and blame themselves when they still scratch.
Narrowband ultraviolet B phototherapy, given two or three times a week in a clinic, is effective for moderate to severe eczema, and it explains a pattern you will see in our comments: people who report that summer sun or a tanning bed helped them. One commenter wrote that the only thing that ever helped him was tanning twice a week, which took five months to work. The guidelines do not endorse tanning beds, because of skin cancer risk, but the sun effect is real biology.
Before the biologics, severe eczema was treated with oral immunosuppressants: cyclosporine, methotrexate, azathioprine and mycophenolate. They work but carry risks that require blood monitoring. Oral steroid bursts such as prednisone clear eczema quickly, but flares often return fast and hard when the course ends, and guidelines recommend against them for routine eczema. Phoilex’s villain inventory names the prednisone taper as part of the steroid story.
Dupilumab, sold as Dupixent, changed eczema treatment when the FDA approved it in March 2017 for adults with moderate to severe disease. It is an injected antibody that blocks the shared receptor for interleukin four and thirteen, the central type two signals, and it was extended over the following years to adolescents, to children from six, and in June 2022 to children from six months old. It is given every two weeks for adults after a loading dose. In trials, roughly a third to four in ten adults reached clear or almost clear skin on Dupixent alone at sixteen weeks, more when combined with topical steroids, and itch improves quickly. Its best-known side effects are eye inflammation, especially conjunctivitis, and a red rash on the face and neck in some patients. It does not suppress the immune system broadly, so it needs no routine blood tests.
The price is the obstacle. Dupixent’s list price was about four thousand one hundred and ninety-three dollars per carton of two injections in January 2026, which makes roughly fifty thousand dollars a year at list price, and insurers usually require patients to show that cheaper treatments have failed first. Patient assistance programmes can bring the cost to near zero for those who qualify, and the paperwork is a commonly reported burden. In Phoilex’s market map, cost appears in one hundred and thirty-five corpus items, and fifty-eight of them sit on the Dupixent doorway, the highest of any door.
Three more biologics have followed Dupixent onto the market. Tralokinumab, sold as Adbry and approved in December 2021, and lebrikizumab, sold as Ebglyss and approved in September 2024, block interleukin thirteen. Nemolizumab, sold as Nemluvio, blocks the interleukin thirty-one receptor and was approved for prurigo nodularis in August 2024 and for eczema in December 2024. Google’s autocomplete already shows the comparison stage: which is better, Dupixent or Ebglyss, Dupixent or Nemluvio, Dupixent or Rinvoq.
The buyer’s view of this shelf is split. Some of the most grateful voices in our own ad comments are Dupixent users; one wrote that after nine years on it she would call it a miracle, and that it is not a steroid. Others describe allergic reactions or eczema returning harder after stopping. The phrase from our corpus that captures the hesitant middle is the woman who can get it and does not want to inject herself for skin. Phoilex’s market map calls this sub-avatar insured but scared.
Upadacitinib, sold as Rinvoq, and abrocitinib, sold as Cibinqo, are pills that block Janus kinases inside immune cells. Both were approved for eczema in January 2022, and both are among the most effective eczema treatments ever tested, with fast itch relief. They carry a boxed warning covering serious infections, death, cancer, major heart events and blood clots, carried over from a large safety study of a related drug in older rheumatoid arthritis patients. Phoilex’s villain inventory counted three hundred and sixty-two mentions of these pills and phrased the flip as the eczema pill with five FDA warnings.
This shelf belongs to the market more than to medicine. The allergy societies’ guideline recommends against elimination diets for eczema, with or without allergy testing. A 2022 meta-analysis led by Paul Oykhman, pooling ten randomised trials with five hundred and ninety-nine participants, mostly young children, found that elimination diets may produce a slight, potentially unimportant improvement in mild to moderate eczema, at low certainty, and raised concern that avoidance can increase the risk of a true food allergy developing. Allergy tests make this worse, because a positive skin prick or blood test often reflects sensitisation, meaning the immune system has noticed the food, without meaning the food causes symptoms.
Probiotic evidence is mixed. Older Cochrane work found little or no benefit for treating established eczema, while a 2024 European allergy society meta-analysis of twenty trials in children found a meaningful drop in severity scores with probiotics, which its authors described as a consistent trend that falls short of a settled conclusion. Oral vitamin D has produced conflicting results, with some trials, including one in Mongolian children with winter-worsening eczema, showing benefit and others none. Fish oil, evening primrose oil and borage oil have mostly failed in trials. Our corpus shows how heavily people lean on this shelf anyway, with four hundred and five mentions of probiotics and gut protocols and three hundred and eighty-seven items blaming diet.
The last shelf is where most direct-response sellers live. Colloidal oatmeal has the strongest standing: it is an FDA-recognised skin protectant under the over-the-counter monograph, with real anti-itch and anti-inflammatory compounds called avenanthramides, and that monograph status is what lets a product legally say it temporarily relieves itching due to eczema. Licorice has a small double-blind trial from 2003 in sixty patients, in which a two percent gel of glycyrrhetinic acid reduced redness, swelling and itch more than a one percent gel over two weeks. Manuka honey has only small pilot studies. Topical CBD has no credible controlled trials for eczema. Tallow, the biggest seller by volume, has no eczema trials at all, though it is a fatty occlusive moisturiser and plausibly helps dry skin like one. Coconut oil showed antibacterial effects against staph in one small trial, and sunflower seed oil supports the barrier while olive oil appears to weaken it. Castor oil, black currant seed oil, apple cider vinegar and essential oils circulate widely on YouTube with little evidence, and vinegar and essential oils can irritate broken skin.
When you lay out the shelves this way, the buyer’s experience makes sense. The things that work best on the biology, steroid creams, the newer prescription creams, biologics and JAK pills, are either feared, expensive, or both. The things that feel safe, moisturisers, natural balms and supplements, help at the edges and are bought again and again. The mainstream fix for the relapse problem, proactive maintenance, uses the very shelf she fears most, and almost nobody explains it to her in a way she believes. That gap between what works and what she will use is the economic space every steroid-free brand, Phoilex included, is selling into. Episode four follows her through the shelves in the order she actually meets them.
Every sufferer walks a road, and most of them walk the same road in the same order, which is good news for anyone who wants to meet them at the right place with the right words. This episode follows that road along four tracks. The first is the adult with long-standing eczema. The second is the parent buying for a baby or child. The third is the person deep in steroid fear or living through topical steroid withdrawal. The fourth is the older adult, who is the largest group of Phoilex buyers. On each track you will see what she tries, in the order she tries it, why each step half-works, and the sentence she says to herself as she moves on to the next one.
Before the tracks, one idea explains why every step on every track seems to work at first. Eczema waxes and wanes on its own. People start something new when they are at their worst, because that is when they are desperate enough to try it. A flare that is at its worst will, on average, ease over the following days and weeks whether or not anything is done, a statistical habit called regression to the mean. So the newest remedy collects the credit for a recovery that was partly coming anyway, and when the next flare arrives, the remedy looks like it stopped working. This single fact explains much of the forum chatter about miracle cures, and it explains why sufferers distrust everything after enough cycles.
She usually starts in childhood, outgrows most of it, and finds it coming back in her teens or twenties, often on her hands, eyelids, neck and the creases of her elbows. Her first stop is the pharmacy. She buys a moisturiser, usually CeraVe, Aveeno, Eucerin or Cetaphil, and over-the-counter hydrocortisone at one percent. The moisturiser helps the dryness, and the hydrocortisone takes a little of the edge off a mild patch. For anything beyond mild eczema on the body, one percent hydrocortisone is too weak, and she uses it in thin smears for a day or two, so it fails. The sentence she says to herself is that creams do not really work.
Her second stop is a general doctor or urgent care. She leaves with a prescription for a mid-potency steroid such as triamcinolone and an instruction to use it twice a day for one or two weeks. This time the cream works, often dramatically, and within days the redness and itch fade. Because she has heard steroids are dangerous and the doctor told her to use it sparingly, she stops the moment the skin looks normal. Within days or a few weeks, the patch comes back in the same place. She repeats this cycle several times over months or years.
Her third stop is a dermatologist, often after a wait of weeks. The visit is short. Phoilex’s research holds a Reddit poster’s account of a dermatologist who looked at her skin for under five minutes and prescribed steroids, and another who wrote that as soon as she says the word eczema, the doctor looks straight at the computer and prints a prescription for a stronger steroid. She leaves with something stronger, sometimes clobetasol, the strongest class. It works again, and then the patch returns again. Our corpus captures this arc in four beats that appear in all four of Phoilex’s sufferer language banks: it works at first, it stops working or needs to be stronger, it comes back worse when you stop, and it thins the skin. A YouTube commenter in our bank put the whole thing in one sentence: “it always cleared my skin but whenever it finishes the eczema comes back worse.”
Her fourth stop is the internet, and here the road forks. On one fork she meets topical steroid withdrawal, through a TikTok video or a news story, and she becomes frightened of the tube in her drawer. On the other fork she meets the root-cause world of functional medicine YouTube, where Dr. Eric Berg’s video on the number one remedy for eczema has more than one and a half million views and Gary Brecka tells her eczema is not skin deep. Both forks lead her to the same conclusion, which is that the answer must be somewhere other than the cream.
Her fifth stop is the inside. She cuts dairy, then gluten, then sugar. She tries an elimination diet, a low-histamine diet, probiotics, vitamin D, zinc, fish oil, and sometimes apple cider vinegar. She switches detergents, buys a shower filter, and changes her sheets to cotton or bamboo. Some of this helps a little, some coincides with a natural lull, and none of it stops the comeback. A comment on Phoilex’s Reddit pull with one hundred and eleven upvotes describes working with a dietitian extensively and finding no rhyme or reason. The sentence she says now is that she has tried everything.
Her sixth stop is one of three places. If her insurance will cover it and she can face the needle, she starts Dupixent, and many people do well on it. If she is deep in steroid fear, she quits steroids and may go through withdrawal, which is track three. Most often, she settles. She uses a steroid in short bursts when it gets bad, a moisturiser most days, and some natural products, and she tells herself that eczema is a lifelong disease she will manage forever. One commenter on our own ads described exactly this pattern of use, writing that she avoids cortisone cream except for a rare flare and then uses it for maybe three nights. That sentence is the valley in a single line, and episode five explains why.
The parent’s road starts earlier and hurts more, because the patient is someone she would trade places with. Eczema in babies often begins in the first months, on the cheeks, scalp and the outer surfaces of the arms and legs. One mother in Phoilex’s Reddit pull wrote that her son’s eczema started at six weeks old, and that the family made the mistake of overusing steroids, a post that drew thirty-five upvotes.
Her first stops are the pediatrician and the baby aisle. She leaves with advice to use fragrance-free products, short lukewarm baths, a thick moisturiser, and often a low-strength steroid. The steroid works, and she feels guilty about using it. In our research, one parent wrote that a pediatric dermatologist told them to use steroids and antibiotics on a toddler’s skin for as long as needed, regardless of the warning on the tube. The tension between the instruction and the warning is the wound this persona carries.
Her nights are the centre of her suffering. She describes putting socks or mittens on her baby’s hands to stop him tearing at his face, holding a crying child at three in the morning, changing bloody sheets, and wet wrapping before bed. Phoilex’s parent persona quotes a mother who wrote that she was “a stress ball trying to contain it,” and that phrase is the emotional core of the parent track.
Her second stage is the allergy hunt. Because eczema in babies is linked to food allergy, she tests, and the tests often come back positive for foods the child eats without trouble, because sensitisation and true allergy are different things. She removes dairy, eggs, wheat, sometimes from her own diet if she is breastfeeding. The guidelines now recommend against elimination diets for eczema and in favour of early introduction of common allergens, because avoidance can make a true food allergy more likely, but many parents never hear that.
Her third stage is the long list. A grandmother who commented on one of Phoilex’s ads described twelve years with her grandson, starting when he was one, with ninety percent of his body covered in raw, weeping, bloody skin. She listed what the family tried: thousands of dollars, support groups, driving hundreds of miles to doctors, natural doctors, elimination diets, bleach baths, seaweed baths, wet wraps and wet suits. Another grandparent wrote that all the doctors do is prescribe stronger steroid creams, recommend the Dupixent shot, or do wet and dry wraps. Notice that grandparents appear repeatedly in our own comments; they are buyers in their own right.
The good news on this track, which many parents never hear clearly, is that most childhood eczema fades. A 2016 meta-analysis in the Journal of the American Academy of Dermatology found that about four in five cases of childhood eczema were no longer persistent eight years after diagnosis, and fewer than one in twenty persisted twenty years later. The children who keep it tend to be the ones with severe or early disease, and they become the adults on track one.
This track needs the most care, because it is where the market is most emotional and where the science is most contested. Topical steroid withdrawal, usually shortened to TSW, describes a severe reaction that some people report after stopping topical steroids, usually after long, frequent use. The skin burns rather than itches, turns bright red or, on darker skin, purple or dark, often spreading beyond where the cream was applied, and may ooze, shed in sheets and lose its ability to hold temperature, leaving people shivering or overheated. Two signs come up repeatedly: the red sleeve, where redness covers the arm and stops sharply at the hand, and elephant skin, the deep wrinkled thickening of the skin over the elbows and knees. Recovery is described as taking months to years.
The idea is older than the internet. The dermatologist Albert Kligman wrote about steroid addiction of the face in 1979. Marvin Rapaport, a California dermatologist, described what he called red burning skin syndrome in a series of patients from the late 1990s onward. In 2015, a systematic analysis in the Journal of the American Academy of Dermatology by Tamar Hajar, Jon Hanifin and colleagues pooled thirty-four studies and concluded that the condition appeared to be real, occurring mostly in women, mostly after prolonged use of moderate to high potency steroids on the face and genitals, and that more research was needed. The International Topical Steroid Awareness Network, ITSAN, founded in 2012, became the patient organisation.
Since then the recognition has grown in steps. The United Kingdom’s medicines regulator, the MHRA, published its own evidence assessment in September 2021, acknowledging that withdrawal reactions can follow long-term or frequent use, and in May 2024 announced that steroid packs would carry potency labels and a withdrawal warning, after two hundred and sixty-seven reports of these reactions between September 2021 and August 2023. In 2025, researchers at the National Institutes of Health led by Ian Myles published provisional diagnostic criteria in the Journal of Investigative Dermatology, based on a small pilot study of sixteen people with withdrawal symptoms compared with eczema patients and healthy controls, and found that people with TSW symptoms had raised levels of a molecule called NAD plus, proposing that drugs such as metformin be tested as treatments. In 2026, a dedicated diagnosis code for the condition was approved for use in the American coding system, which will let researchers start counting it. At the same time, many dermatologists remain unconvinced; in a 2025 survey of seventy dermatology fellows and trainees in Australia and New Zealand, fifty-nine percent said they do not consider TSW a formal clinical entity.
Nobody knows how many people it affects, because until now there were no agreed criteria and no code. The largest patient survey, led by ITSAN’s president Kathryn Barta and published in the Annals of Allergy, Asthma and Immunology in 2022, gathered responses from one thousand eight hundred and eighty-nine adults and two hundred and seventy-one caregivers of children. The adults had used prescription steroids for an average of fifteen point three years, the children for three point six. A large share of respondents said they had symptoms consistent with withdrawal after stopping. Because people were recruited through patient groups, the survey cannot say how common withdrawal is in the general eczema population.
Here is how the road itself usually runs. The person on this track usually used steroids for years, often moving up the strength ladder. The young creator Jada Jones, featured in the New York Post’s 2025 article on TSW, said that when she asked to come off steroids as a teenager, her dermatologist told her she was young and would never have to go through that, and moved her up to the strongest class. In June 2022 she developed bruise-like purple spots that did not look like eczema and then spent three to four months bedridden. Her stated end point, quoted in the Post, is mild eczema that she would rather tolerate for the rest of her life than ever go through withdrawal again.
On this track, people quit steroids cold turkey and often quit moisturisers and sometimes bathing as well. They join Reddit’s withdrawal communities, Instagram and TikTok, where the hashtag has grown fast, and where a 2023 study rated the most-watched YouTube videos on the topic as poor in reliability. Phoilex read five long recovery journeys end to end, and the striking finding is how they describe healing. All five credit subtraction: time, stubbornness, a doctor who held their hand, a paid workbook, the community. One said no product will miraculously heal you, and another said the pharmaceutical creams were a waste of money after trying ten of them. And yet every one of the five kept something on the shelf, and two independently kept a zinc spot treatment on the worst patches only. One wrote that a zinc cream used mainly on the oozing and weeping parts was the only thing she still uses now.
A sixth journey from a buyer-intent search, a video with five hundred and thirty-five thousand views, complicates the picture. That woman used steroids daily for thirteen years, quit cold turkey, credits a moisturiser by brand for keeping her eczema from coming back, and went back onto steroids in a rationed way. Her complaint was the instruction gap: patients are prescribed many things without being told how to use them or how not to. She also drew the same line as the others, saying she would not put an occlusive over her entire body but that it was perfect for the really dry cracked spots.
Track three carries important limits for anyone marketing a product. The person in full withdrawal already believes steroids are the villain, so telling her so earns entry and sells nothing. Phoilex’s TSW persona notes that she is product-skeptical and responds only to insider credibility. The more valuable buyer is the woman one step earlier, still on the cream, recently moved up a strength, frightened by the withdrawal stories, and stuck because her doctor says it is safe. The New York Post read in the drops folder describes her as Jada in 2019.
This is the track the course has to spend real time on, because these are most of Phoilex’s buyers. In the ninety days to late October, people aged sixty-five and over accounted for eight hundred and thirty-seven of the account’s one thousand three hundred and ninety-one purchases.
Some on this track have had eczema their whole lives. One commenter on our ads wrote that she was sixty-one and had had chronic, body-covering eczema for sixty-one years. Others had it as children, lost it for decades, and saw it return in their fifties or sixties, sometimes around menopause; Phoilex’s market map lists menopause and hormonal mentions in thirty-seven corpus items and a sub-avatar called it came back at forty-seven. Others developed it for the first time late in life, often on the legs and trunk, on top of the dry, thinning skin of age.
Their road has its own stops. They have usually seen several doctors and dermatologists. They have been on the steroid ladder longer than anyone, and their thinner skin makes atrophy and bruising a real worry. They often take several medications and manage other conditions, which makes them wary of anything new taken by mouth. They spend money; one commenter wrote that he had spent over one hundred thousand dollars on doctors, clinics, snake oils and medications, and another said her husband had seen five dermatologists in four years, with a cream costing over two thousand dollars. Many of them distrust the medical system after decades of management without resolution, and some have stepped away from doctors entirely. One commenter, aged sixty-six, wrote that the best thing she ever did was stop seeing her doctor, and that she now uses only cotton, natural soap and no detergent or dryer sheets.
Many of the people on this track are also caregivers for someone else. The grandparents in our comments, buying for a grandson who scratches until he bleeds, belong here too, and the long story ads that Meta delivers to people over sixty-five reach them as both sufferers and protectors. When Phoilex’s under-forty-five plan notes that our winning native ads are stories about years on a drug and outcomes before seventy, it is describing ads that fit this track.
Put the tracks side by side and the shared pattern is clear. Every track begins with something that works for a while, and every track then meets the comeback, the patch returning in the same place after treatment stops. Every track then splits between going up the ladder to something stronger and going sideways to something gentler or internal. And every track ends, for most people, in an uneasy settlement of bursts, moisturisers and hope, held together by a belief that the disease can only be managed. Episode five names the exact step where most people stall and the belief that keeps them there.
Every chronic condition has a place where most sufferers stop moving, a stage they reach after the early hope and before any real resolution, where they settle into a belief that explains their situation and keeps them there. This course calls that place the valley, and knowing the valley precisely is worth more to a marketer than any amount of general sympathy, because an ad that names the valley in the sufferer’s own words feels like it was written by someone who has stood in it, and a page that walks her out of it is the only kind of page this sophisticated market will trust. This episode defines the eczema valley, shows the evidence for it from Phoilex’s own research with counts and file names, adds the outside evidence, and then describes the two side valleys that parents and the steroid-withdrawal community sit in.
The eczema valley is the same-spot comeback, and the belief it creates. The sufferer has treated a flare, usually with a steroid cream, the skin has cleared, she has stopped treatment the moment it looked normal, and the flare has returned in the same place within days or weeks, often feeling angrier than before. After this happens enough times, she draws a conclusion that feels like wisdom. Treatments that only work while you use them are not real treatments, and a real fix is one you can stop. From that conclusion she takes one of two paths. Either the cream itself is the problem, because it only works while she uses it and things come back worse when she stops, or the cause must lie somewhere inside her, in her diet, her gut, her immune system or her stress, because nothing on the surface ever lasts.
Here is why that belief keeps her stuck. Eczema is a relapsing condition in which the quiet skin between flares is still weak and still primed, especially at old sites, as episode two explained. The approach that the evidence supports for breaking the relapse pattern is maintenance: keeping the barrier supplied every day and treating the usual sites lightly while they look clear. Her valley belief rejects maintenance as a category, because maintenance is, by definition, a treatment that only works while you keep doing it. So she treats reactively, in short bursts at the worst moments, stops early, and meets the comeback again. Each comeback confirms the belief, and the belief guarantees the next comeback.
The strongest single piece of evidence comes from the sufferer-language study that Phoilex ran in October 2026, saved at research/eczema-voc-20261028/STUDY.md. It mined four separate banks of sufferer language: one hundred and thirty-six organic TikTok sufferer transcripts, five long YouTube recovery journeys plus the New York Post feature, about two thousand five hundred YouTube comments together with our three hundred and eighty-six ad comments and the Gladskin ratings, and twelve hundred high-signal records from r/eczema and r/SkincareAddiction. The study reports that the single most corroborated story in the entire corpus, present in all four banks from hundreds of independent people, is a steroid arc in four beats. In the first beat it works, in lines such as “Steroid cream would clear it up completely.” In the second it stops working or needs more, and one Reddit poster said she needed a stronger and stronger cream until it stopped working altogether. In the third it comes back worse when you stop, in lines such as “it always cleared my skin but whenever it finishes the eczema comes back worse” and “the eczema came back ten times stronger.” In the fourth it thins the skin or only masks the problem, in lines such as “the only side effect they warned me about was the thinning of the skin,” and “a band-aid and never a cure.”
The second piece is the belief ranking in personas/MARKET-NOW.md, built from one thousand seven hundred and sixty-nine Reddit items across r/eczema, r/AtopicDermatitis, r/SkincareAddiction and r/TopicalSteroidWithdrawal. Its first-ranked belief, described as near-universal and hard-won, is that creams and steroids only manage eczema and do not cure the root cause, anchored by a comment with two hundred and twenty-three upvotes saying nobody claims steroids do not work, they just do not cure the root cause. The file’s summary of where the market is stuck reads that sufferers oscillate between hope and despair, have stopped believing a cure exists, and are sick of the question “have you tried a cream,” a line that drew eight hundred and six upvotes.
The third piece is the objection ladder in MARKET-MAP.md, which counts corpus items mentioning each reason a sufferer has not yet bought. The fear that a product will make her skin worse appears in two hundred and ninety-nine items and ranks first or second on every doorway. The diet and gut belief appears in three hundred and eighty-seven items and ranks in the top two on every doorway. Having tried everything appears in ninety-one items, the belief that treatment only manages it in seventy-nine, and the experience of something that worked and then stopped in fifty-two. Read together, these objections are the valley seen from five angles: a treatment that worked, stopped, made things worse when withdrawn, and pushed her inward.
The fourth piece is search behaviour. Phoilex’s Google and Amazon autocomplete pull, in research/suggest-mining-20260812.md, found four hundred and sixteen of two thousand nine hundred and seventy-three unique Google suggestions in a cluster about fear, worsening and withdrawal, including steroid cream making eczema worse, steroid cream rebound and should I stop using steroid cream. It also found a disambiguation cluster that captures the moment of being stuck better than any belief statement: topical steroid withdrawal versus eczema, and topical steroid withdrawal versus eczema flare. She is standing in front of a flare and cannot tell whether it is her disease or her cream. The drops research, summarised in the Liverty fact bank, adds that Google’s autocomplete produced eighty-five suggestions built around eczema coming back after stopping steroid cream or coming back in the same spot, the largest cluster in that pull.
The fifth piece comes from our own ad comments, in research/own-ad-comments.jsonl. Of three hundred and eighty-six comments, thirty-eight mention steroids, twenty-nine mention Dupixent, twenty mention diet, nineteen mention probiotics or the gut, and thirty-four mention itch. Several describe the valley exactly. One commenter wrote that she avoids cortisone cream except for a rare flare and then only for maybe three nights, which is reactive treatment described as a virtue. Another wrote that he started with hydrocortisone, moved up to clobetasol and several other prescriptions, and could not say the medication helped, because the eczema “ebb and it flows” and seemed tied to his mental state. A grandparent wrote that her grandson stopped Dupixent for a month and it came back worse. Each of these is the same experience: something works while it is used, and the condition returns when it stops.
The sixth piece is the recovery corpus in MARKET-NOW section D, five long TSW journeys read end to end and stored in copy-hub/arcs. They show where the valley leads when the cream belief wins. All five credit subtraction for their recovery, and their own villain is the topical routine itself; one woman described her skin as addicted to moisturisers. The persona files add the emotional texture. The lifelong sufferer in personas/01-lifelong-sufferer.md holds the root belief that this is just who she is and she can only manage it. The diagnosis file distils her as depleted, hopeless and resigned.
Mainstream dermatology describes the same valley from the other side and gives it different names. The first name is under-treatment driven by steroid fear. The 2017 systematic analysis by Albert Li and colleagues in JAMA Dermatology found corticosteroid phobia in between twenty-one and almost eighty-four percent of patients and caregivers across sixteen studies, and in the two studies that compared adherence directly, fearful patients skipped treatment far more often, forty-nine percent against fourteen percent in one and twenty-nine against ten in the other. A frightened patient uses too little, for too short a time, and stops at the first sign of improvement, which is exactly the reactive pattern of the valley.
The second name is so-called steroid resistance, and here the literature is surprising. Many patients and doctors believe that steroid creams stop working with repeated use, a phenomenon called tachyphylaxis. A 2013 study of the evidence by Taheri, Cantrell and Feldman in the Dermatology Online Journal found that tolerance appears in some laboratory measures, but that no clinical trial supports the idea that topical steroids lose effectiveness over time in patients. In a small study of twelve eczema patients who had previously failed steroids, all improved within one week on a potent steroid when their use was supervised, and the authors pointed to poor adherence as the likely explanation for the earlier failure. Mainstream dermatology’s reading of the second beat of the steroid arc, it stopped working, is therefore that the cream was used too little or too briefly, while the market reads the same beat as proof of addiction.
The third name is relapse, and the evidence on preventing it is the strongest in this whole course. When patients cleared with a steroid then used it twice a week on their usual sites instead of stopping, the 2003 Berth-Jones trial found the average time to relapse stretched from about six weeks to more than sixteen. The 2011 Schmitt meta-analysis put the relapse risk with proactive fluticasone at about forty-six percent of the comparison, and a later Cochrane analysis of weekend therapy landed at a relative risk of about forty-three percent. Both American guidelines recommend this maintenance. Few patients in our corpus have ever heard of it, and the valley belief makes it hard for them to accept, because it asks them to use the thing they fear on skin that looks fine.
The fourth outside view comes from the steroid-withdrawal literature, and it is the reason the valley cannot be dismissed as pure misunderstanding. Some people who used potent steroids for years, especially on the face, do develop severe reactions when they stop, as the 2015 Hajar analysis, the 2021 MHRA assessment and the 2025 NIH criteria all describe. Abruptly stopping a potent steroid after long use can also produce a rebound flare, which is why tapering is standard advice. So the market’s reading of the third beat, it comes back worse when you stop, is partly true. The valley is built from a real experience, misread in a way that leads people away from the approach that would most help them.
From the valley there are two common exits, and both tend to circle back. The first exit is up the ladder. She asks for something stronger, gets clobetasol, then perhaps a course of prednisone, then Dupixent or a JAK pill. Each step works, and for many people the biologics work very well. But the valley belief comes with her, and when she stops the stronger treatment, the disease returns, as one Reddit poster in our bank wrote of Dupixent, ten million times worse. In Phoilex’s market map, the Dupixent doorway’s top objections are the fear of it making things worse, in seventy-eight items, and cost, in fifty-eight.
The second exit is sideways and inward. She looks for the root cause in diet, gut, detergent, water or stress, and the subtractions sometimes coincide with a natural lull, which feels like proof. Our own ad comments are full of these confident cures: probiotics and oil of oregano, a low-histamine diet, avoiding preservatives, eating organic olive oil, tanning beds, acupuncture, no detergent at all. Some of these people may have found something that helps them, and many found a lull. When the next flare comes, the search starts again, and the diet villain grows larger, which is why diet and gut ranks in the top two objections on every doorway.
Parents sit in a related valley with a different shape. Phoilex’s parent persona describes it as a trap with two jaws. On one side is the steroid she now fears, the tube she believes may be making her child worse. On the other side is nothing, because a screaming child at three in the morning does not care about her principles. She swings between the two, using steroid in guilty bursts and then withholding it, which produces the same reactive pattern as the adult valley, with guilt layered on top. Her open loop, in the persona’s words, is whether she is making it worse with the steroid she is scared of, and whether something can calm her child without it. Many parents in this valley also hold an inward belief, that the cause is a food, and the elimination diets they adopt can make the child’s eating harder without fixing the skin.
The third valley belongs to people already in withdrawal or committed to avoiding steroids entirely. Their belief is that they must endure the raw skin, without any product, for as long as it takes. Phoilex’s TSW persona describes them as product-skeptical and sometimes moisturiser-skeptical, the hardest people to sell to. The recovery corpus shows that most of them do recover substantially over months to a year or more, describing themselves as ninety or ninety-five percent healed, and that recovery is not a straight line; one woman had three good months and then relapsed for four more. Their valley is endurance without support, and the evidence from their own stories is that even the purists kept one gentle thing on the worst patches.
People in the valley share an emotional state that shapes how they read any ad. They are exhausted, often from years of poor sleep. They are ashamed of how their skin looks, and they hide it under long sleeves in summer. They distrust doctors, because, as one sufferer in our research put it, she had seen six dermatologists including at the Mayo Clinic with no answers. They distrust products, because they have bought so many. They distrust ads most of all, and in our own comments, people called our story ads AI-generated, asked whether the company was real, and said they would only believe us if someone answered their questions. One wrote that the bottom line for her was definitely not another cream or a miracle probiotic. Another objected that if creams do not penetrate and heal, a tube of gel is not going to provide what her skin needs.
That last objection is the valley speaking directly to Phoilex. A topical product sold into this valley is, on its face, another surface treatment that will only work while she uses it, which is the very category the valley has taught her to reject. Any honest strategy has to start from that fact.
Knowing the valley changes which hooks make sense. A hook that names the comeback in her own terms, a patch that clears with the cream and returns in the same spot, describes the experience she has had dozens of times, and it does so without asking her to accept a mechanism first. A hook built on the disambiguation search, whether the flare in front of her is her eczema or her cream, meets her at the exact moment of doubt that her own searches reveal. Phoilex’s suggest-mining file ranked this angle as the strongest untested asset on the board in August 2026. A hook that agrees with her that the cream only manages it earns trust from almost everyone in the valley, because it is the most widely held belief in the corpus, and the work of the page is then to move her from that agreement toward a better plan for the quiet skin.
The valley also tells you what to avoid. Telling her she has been using the cream wrong lands as blame, and the corpus shows she has already been blamed by doctors, relatives and forums. Telling her the cure is inside sends her deeper into the diet search that has already failed her. And promising that a product will stop the comeback forever contradicts every experience she has had, which reads to her as the voice of someone who has never had eczema. The recovery stories put the credible ceiling at about ninety percent healed with occasional flares, and promises above that ceiling sound like an outsider talking.
If you want one sentence to carry into every meeting about this brand, use this one. Most eczema sufferers are stuck in a loop of treating flares in short, frightened bursts, stopping as soon as the skin looks clear, watching the flare come back in the same spot, and concluding that the cream is the enemy or that the cause must be inside them, a conclusion that keeps them away from the steady, boring maintenance on the usual spots that the evidence says would break the loop. Episode six is about the counterintuitive truths that move people out of this loop, and how Phoilex’s own philosophies sit against them.
An aha, in the sense this course uses the word, has three parts. It contradicts something the sufferer already believes, it comes with a mechanism she can understand in one or two sentences, and it gives her a way to check it on her own skin without trusting anyone. The third part matters more in eczema than in almost any other market, because this buyer has been told many things by many people and has learned to trust only what she sees. This episode lays out five ahas in order of importance, then sets Phoilex’s three philosophies against them, and labels each claim as science fact or marketing frame. Your rule, Kalp, is that a frame is judged on whether the buyer acts and science is judged on whether it is true, and this episode keeps those two judgements separate.
The belief it contradicts is the valley belief from episode five. She believes that when the skin looks clear the flare is over, and that a flare returning in the same spot means the treatment failed or caused it.
The mechanism takes two sentences. After a flare calms, the skin in that spot keeps a weak top layer and keeps a pocket of primed immune cells for weeks, so it looks normal while it is still halfway to the next flare. When an ordinary trigger comes along, that spot tips over first, which is why the flare returns in the same place.
The proof she can check on her own skin is a spot map. For eight weeks she photographs and marks every place that flares, and almost everyone who does this finds that most of their flares return to the same small number of sites, often three to five. That observation alone breaks the idea that flares are random. The second part of the check is to look after those sites on the days they look fine, a couple of times a week, and count the flares over the next eight weeks against the previous eight.
The evidence status is science fact, and it is the strongest evidence in the whole field. Proactive treatment of the usual sites after a flare clears roughly halves the chance of relapse in randomised trials, with a relative risk around forty-three to forty-six percent of the comparison in the pooled analyses described in episodes three and five. In mainstream dermatology, the treatment applied to those sites is a low or mid-potency steroid or a calcineurin inhibitor twice a week, plus daily moisturiser. The deeper lesson is behavioural. Most people treat the flare and ignore the quiet skin, and the quiet skin is where the next flare is being prepared.
This aha is counterintuitive for a specific reason: it asks her to treat skin that looks fine, which feels wasteful and, for someone frightened of steroids, dangerous. The same idea reframes her past in a way she can accept: the cream did work, and the comeback came from what happened after she stopped, which absolves her without blaming her.
The belief it contradicts is that itch is an allergic reaction, so an antihistamine should stop it. Many sufferers take Benadryl or Zyrtec every night and blame themselves, or their eczema’s severity, when they still scratch.
The mechanism is that eczema itch is mostly driven by immune messengers called interleukin thirty-one, four and thirteen acting directly on the itch nerves in the skin, with histamine playing a small part, so antihistamines block the wrong signal.
The proof she can check is her own history. If an antihistamine made her sleepy without stopping the itch, she has already run the experiment. A second check is that cooling the skin, pressing or pinching instead of scratching, and putting a thick, plain moisturiser on an itchy patch often reduce itch faster than a pill.
The evidence status is science fact. The 2017 Cell paper by Oetjen and Kim, and the success of drugs aimed at interleukin thirty-one and the interleukin four receptor, support the mechanism, and both American guidelines advise against antihistamines as eczema treatment. Phoilex’s villain inventory flagged this as a candidate angle with three hundred and seventy corpus mentions and called it a genuine prediction error, meaning a fact the market does not expect.
The belief it contradicts is the inward turn, the conviction that the real cause of eczema is something she eats, which ranks in the top two objections on every one of Phoilex’s doorways with three hundred and eighty-seven items.
The mechanism is that eczema is a disease of the skin’s barrier and its immune response, and food allergy, when present, mostly travels alongside eczema in young children with severe disease rather than causing it in adults. The direction often runs the other way: inflamed, broken skin is one route through which food allergies develop in the first place, which is why early feeding of peanut to high-risk infants cut peanut allergy by about four-fifths in the LEAP trial.
The proof she can check is again her own history. If she cut dairy or gluten strictly for three months and still flared, food was not the main lever. If she suspects one specific food, the honest test is a clear reaction within hours of eating it, such as hives, swelling or vomiting, which is food allergy and needs an allergist, against the slow, ambiguous worsening that people often attribute to food.
The evidence status is science fact for adults and for the general population of children, with a real exception for some young children with severe eczema and proven food allergy. The 2022 Oykhman meta-analysis found at best a slight, potentially unimportant benefit from elimination diets, and the allergy guideline recommends against them. For marketing, the market map already shows the effect: the diet villain wins as an ad opener because it names a hope that has failed her, and our research notes that “it was never your diet” lands as relief, never as an attack.
The belief it contradicts is that flares strike at random, with no logic she can drive, a phrase the brief records from the lifelong sufferer persona.
The mechanism is that primed skin plus an ordinary push produces a flare after a delay. Dry heating in winter, a sweaty week, a run of poor sleep, a stressful stretch at work or a cold all increase inflammation quietly, and the visible flare arrives days later. Stress is the trigger sufferers name most often; the 2020 National Eczema Society survey found it named by fifty-seven percent of women and forty-one percent of men, and 2026 work in mice traced a nerve pathway from stress into the skin.
The proof she can check is a simple log kept alongside the spot map: a line a day for sleep, stress, heat and weather. Within two months most people see a pattern, usually a delay of a few days between a bad stretch and a flare at their usual sites.
The evidence status is mostly science fact for the triggers and the delay, with the mouse work labelled as early. The marketing value is that it replaces randomness with predictability, which addresses the feeling of being at the mercy of her skin. It also supports the timing of maintenance: the days after a stressful week are the days to look after the usual spots.
The belief it contradicts is that any steroid use is a step toward withdrawal, so the safest course is to use as little as possible, as late as possible.
The mechanism has two halves, and both must be told honestly. The first half is that the documented harms of topical steroids, thinning, stretch marks and withdrawal reactions, are linked mainly to long, frequent use of moderate to potent steroids, especially on thin skin such as the face and genitals, as the 2015 Hajar analysis and the 2021 MHRA assessment describe. The second half is that fear leads to under-treatment, under-treatment leads to more flares, and more flares lead to the large rescue courses of potent cream that carry the most risk.
The proof she can check is to look at her own use. If she has used a potent steroid every day for months on her face, her fear is grounded and she should talk to a doctor about tapering and alternatives. If she has used a mid-strength steroid in short bursts on her arms, her risk profile is very different.
The evidence status is science fact on both halves, with the frequency of withdrawal still unknown. This is the aha where the market and mainstream dermatology diverge most sharply, and where Phoilex must be most careful. Mainstream dermatology says the main problem in eczema care is fear causing under-treatment. A large and loud part of the market says the main problem is the steroid itself. Both are pointing at real things. A brand that pretends either side is simply wrong will lose the people on that side.
Phoilex’s documents hold three philosophies. Each one combines some science fact with a marketing frame, and each has a record of what buyers did when it ran, so the sections below take them one at a time.
The claim, in its strongest form in philosophy-1-deepened.md, is that every application of a steroid cream causes the skin’s own cortisol to crash below its starting level when the cream wears off, that this crash triggers the next flare, that a crash flare is impossible to tell apart from a normal flare, and that the sufferer therefore manufactures her own flares by using the cream at all. It argues by cigarette logic that you should stop before the extreme, and by analogy to the opioid crisis that a trusted prescription can author the disease it treats.
The science facts inside it are these. The skin does make its own cortisol, through a local version of the body’s stress hormone system, described in a series of papers by Andrzej Slominski. Topical steroids are synthetic glucocorticoids. Stopping a potent steroid abruptly after long use can cause a rebound flare, which is why doctors taper. Withdrawal reactions after long, frequent use are acknowledged by the British regulator and now have provisional diagnostic criteria from the National Institutes of Health.
The marketing frame is the per-use crash. There is no study showing that a single application, or ordinary intermittent use, drives the skin’s cortisol below baseline and triggers the next flare, and the brand’s own internal notes say exactly this, describing the argument as reasoning the reader there from accepted facts. The evidence that most directly contradicts it is the proactive treatment data: if each application scheduled the next flare, twice-weekly steroid use on clear skin would increase flares, and in trials it roughly halves them. The tachyphylaxis evidence, as episode five showed, is also thin. So, judged as science, the strong form of philosophy one is not supported.
Judged as a frame, the record is mixed and mostly positive. The gel’s biggest ad, the twelveyears story of years on the steroid cream, spent four thousand two hundred and thirty-five dollars at a return of one point five two against a break-even of one point five. The longest-running competitor in the category, Smiles And Joys, has run a steroid-free natural cream against the steroid cream since 2021. The New York Post’s withdrawal article, which named Phoilex, is reported to have driven a large burst of sales, though that figure is unverified. The frame works because it matches the steroid arc that appears in all four banks of sufferer language. Its risks are a medical claim that a dermatologist can take apart in one comment, as one did under our own ad, and a temptation to tell people to stop prescriptions, which the brief bans. The safe version of philosophy one is the version the market already tells itself: the cream works while you use it, it comes back when you stop, the strength creeps up, and the skin thins. Every one of those beats is either documented or experienced, and none requires the per-use crash.
The claim, in philosophy-2-broken-wall.md, is that eczema skin was born short on ceramides because of a fault in the protein it uses to build its top layer, that water leaks out and irritants get in, that the flare is the skin fighting what got in, and that putting the missing fats back, on the skin, is the fix that steroids and diets never provided.
The science facts are strong. Filaggrin mutations are the strongest genetic risk factor for eczema, eczema skin is low in ceramides, the barrier defect lets water out and irritants in, and moisturisers reduce flares and the need for steroids.
The frame is the part that says born short, one missing ingredient, and put it back. Filaggrin faults are found in a minority of patients, common in northern Europeans and rare in many other populations. Ceramide loss is partly caused by the inflammation, so putting ceramides back without calming the inflammation leaves half the loop running. Daily moisturiser from birth did not prevent eczema in two large trials. And ceramide creams have not been shown to beat ordinary good moisturisers. Philosophy two is the most scientifically defensible of the three, and its promise of a fix by replacement is still a frame.
Judged as a frame, its record is weaker in the feed than on the shelf. Phoilex’s stage zero research found that the one direct-response seller running a barrier pitch on eczema peaked at one thousand one hundred and fifty-one engagements, while pharmacy brands selling the same argument without any story, CeraVe above all, sell tens of thousands of units a month on Amazon. MARKET-NOW notes that the word ceramide appeared only nineteen times in one thousand seven hundred and sixty-nine Reddit items, so it is unfamiliar as a concept, while Amazon autocomplete shows people searching for eczema cream with ceramides. The market map now treats this philosophy as the constant mechanism on every page, which fits its strength: it is a good explanation once someone is reading, and a weak hook for stopping a scroll.
The claim, used for the Liverty drops, is that the gel works on the outside and the drops work on the inside, through stress, sleep and the way the body handles its own cortisol, led by licorice root, which the brand’s listicle calls a plant steroid.
The science facts are real and narrow. Glycyrrhizin, the main compound in licorice root, inhibits an enzyme called eleven beta hydroxysteroid dehydrogenase, which turns active cortisol into inactive cortisone, so cortisol stays active longer; this was shown in human skin in a 1990 Lancet paper by Teelucksingh and colleagues. A 2020 double-blind trial by Xu and colleagues in one hundred and ninety-nine adults with chronic eczema across six centres found that oral compound glycyrrhizin capsules taken with a mild steroid cream beat the cream alone over twenty-eight days, with forty-eight percent reaching a seventy-five percent improvement in severity against twenty-one percent. Stress is the trigger sufferers name most. Lemon balm improved sleep in one small trial.
The frame is the plant steroid label and the claim that the drops address the reason it comes back. No trial of the drops exists, the doses of each herb are not published, the trial evidence belongs to a pharmaceutical glycyrrhizin preparation, and the liver story that the brand once told is true for psoriasis and not for eczema, where fatty liver rates in patients match controls. There is also an irony worth naming. The drops’ best-supported mechanism keeps cortisol active for longer, which is a steroid-like action, so a page that runs philosophy one’s cortisol villain alongside philosophy three’s plant steroid hero argues against itself.
Judged as a frame, the drops have not yet found a winning version. Over ninety days the drops ran at a return of about point nine, below break-even, with ninety-seven percent of spend on long native stories, many of them borrowed from the gel. The best small results came from ads that led with the drops themselves. The proven inside-out sellers in the category, such as Skinesa, name a cause the buyer can picture, usually the gut, in short videos that blame the cream mildly.
There is one place where the strongest aha, the science and Phoilex’s product all meet, and it is worth more than any of the three philosophies on its own. Aha one says the spot that keeps coming back needs care on the days it looks fine. The recovery stories in our corpus, from people who quit every cream, show that the one thing they kept was a gentle treatment on the worst patches only. The product-crediting creator with five hundred and thirty-five thousand views drew the same line, saying an occlusive was not for the whole body but was perfect for the really dry cracked spots, and the product Phoilex sells is a spot gel. MARKET-NOW section D turned this into a positioning line: the one thing you keep when you put the rest down.
Be honest with yourself about the limits of that bridge. Mainstream maintenance uses an anti-inflammatory drug, and a steroid-free gel with ceramides, colloidal oatmeal and botanicals is a much gentler anti-inflammatory than fluticasone. No trial shows that the gel matches the relapse prevention of proactive steroid therapy. The brand’s own figures, seventy-four percent reporting fewer flare-ups after eight weeks and ninety-three percent reporting itch relief for four to twelve hours, come from a small trial of nineteen people that the New York Post repeated. So the claim the evidence can carry is narrow and still powerful: keep the usual spots supplied and calm on the good days, with something gentle enough to use every day and on thin skin, and keep everything else your doctor has you on. That is aha one, translated into a product the market will actually use, and it never asks her to stop a prescription.
To close, here is the sorting in plain sentences. Science fact: the barrier is weak and short on ceramides in eczema skin. Science fact: filaggrin faults raise risk, in a minority. Science fact: the itch is mostly not histamine. Science fact: clear skin keeps priming at old sites, and proactive maintenance halves relapse. Science fact: elimination diets help adults very little. Science fact: withdrawal reactions exist after long, frequent, potent use, with unknown frequency. Science fact: glycyrrhizin keeps cortisol active and helped a steroid cream in one trial. Marketing frame: each steroid application crashes cortisol and schedules the next flare. Marketing frame: you were born short of one ingredient and putting it back fixes eczema. Marketing frame: licorice is a plant steroid that treats the reason it comes back. Marketing frame that the evidence can support if phrased carefully: the one gentle thing you keep on the spots that keep coming back. Episode seven runs through the market’s common myths at speed.
This episode is a rapid run through the beliefs you will meet in comments, forums and competitor ads, with the evidence on each. The point of learning them as a set is speed. When a buyer writes under an ad that her eczema is a detox, or that steroid creams are the same thing bodybuilders inject, you should know in a second where that belief comes from, how much truth it holds, and how to answer it without insulting her. The myths are grouped into four clusters: what causes eczema, steroids, the other treatments, and natural remedies.
Many people believe eczema is contagious, and parents of children with eczema often report other parents keeping their children away. Eczema itself cannot be caught from another person. The infections that sometimes ride on top of it can spread, and one of them, eczema herpeticum, where the cold sore virus spreads quickly across eczema skin as clusters of punched-out sores with fever, is a medical emergency worth knowing about.
A common belief, especially among older relatives, holds that eczema comes from poor hygiene. The evidence points the other way: frequent hot washing and harsh soaps strip the skin’s fats and make eczema worse, which is why dermatologists recommend short lukewarm baths and gentle cleansers, and why a nurse washing her hands forty times a shift is a classic hand eczema patient.
Sufferers often hear from family and doctors that eczema is just dry skin, and they resent it. Dry skin is part of eczema, and eczema is also an immune disease with inflammation, itch nerves turned up and bacterial overgrowth, which is why moisturiser alone rarely controls a real flare. Our sufferer-language study found that the phrase about it being more than dry skin is exactly the re-attribution sufferers make themselves.
The belief that food allergy causes eczema is the biggest myth in the market by volume, with three hundred and eighty-seven diet items in Phoilex’s corpus. Food allergy is more common in young children with severe eczema, and in a minority of them a specific food can worsen it, but for most children and almost all adults food is not the driver. Elimination diets produce at best a slight benefit in pooled trials and can raise the risk of developing a true food allergy, so both American guidelines recommend against them.
The idea that eczema is a gut problem, often called leaky gut, comes largely from functional medicine content, and our corpus counted four hundred and five mentions of probiotics and gut protocols. The gut microbiome and the immune system are connected, and some trials of probiotics in children show modest improvements in severity scores. The evidence does not show that fixing the gut cures eczema, and many people in our comments describe gut protocols that did not stop their flares.
Some sellers and commenters describe eczema as the body detoxing through the skin, or as a sign of a toxic liver. The skin is not a detox organ in that sense, and eczema has no established link to fatty liver; one study found fatty liver in about a quarter of people with moderate to severe eczema, the same rate as in people without it. Psoriasis is different, with a real link to fatty liver, which is why Phoilex’s drops research allows liver language only on psoriasis angles.
The belief that eczema is purely genetic, so nothing can be done, comes from doctors as often as from patients. Genes such as filaggrin raise the risk, and so do environment, climate, the skin’s bacteria and the immune system, and the disease is highly treatable even when it is not curable. Phoilex’s own hook bank turns this belief around by agreeing that it is genetic and arguing that this is the reason it can be managed at the skin.
Many sufferers believe stress causes eczema. Stress is the trigger they name most often, and it can worsen flares through real nerve and hormone pathways, but stress alone does not create eczema in someone without the underlying barrier and immune tendency. The useful version of this belief is that a hard week often shows up as a flare a few days later at the usual spots.
Parents are often told that children always grow out of it. Most do, with about four in five childhood cases no longer persistent eight years after diagnosis in one large meta-analysis, and a minority carry it into adulthood, usually those with severe or early disease. Parents of those children often feel misled when the promised end does not arrive.
Some commenters under our ads tie the start of a child’s eczema to vaccines, and one grandmother described severe skin disease beginning after her granddaughter’s shots. Large studies have not found that vaccines cause eczema, and the timing is easy to misread, because infant eczema usually begins in the same months that the main childhood vaccines are given. A parent who saw the rash appear the week after a vaccine is reporting a real sequence of events, and the honest answer respects what she saw while explaining the coincidence of timing.
The belief that eczema is a children’s disease is one of the most commercially important myths for Phoilex. About one adult in four with atopic dermatitis developed it in adulthood, and new cases rise again from the fifties onward. Our account’s buyers are mostly over sixty-five, and many of them have been told for years that what they have is just dry, ageing skin.
Many people believe that eczema and psoriasis are the same thing, or that a cream for one works the same on the other. Both are chronic inflammatory skin diseases that come and go, and they differ in their immune pathways, their look and their treatments, with psoriasis forming thick, silvery, sharply bordered plaques on elbows, knees and scalp and eczema forming itchier, less sharply bordered patches in the creases and on the hands and face. Phoilex sells into both markets and carries a National Psoriasis Foundation Seal, and its product page receives many questions from people with psoriasis, seborrheic dermatitis, dyshidrotic eczema and other variants who want to know whether it fits their diagnosis.
A related belief holds that eczema is rare or mild on darker skin. Atopic dermatitis is, if anything, more common in Black children in the United States, and it is often under-rated because redness shows as grey, brown or violet, and because the dark or light marks it leaves can last for months after a flare.
Parents often believe an allergy test will tell them exactly which foods to cut. Skin prick and blood tests detect sensitisation, meaning the immune system has noticed a food, and a positive result often appears for foods a child eats without any reaction. Acting on a panel of positive tests is how many families end up on restrictive diets that do not help the skin, which is why allergists now interpret those tests alongside a clear history of reactions.
People often believe that steroid creams are the same thing as the steroids bodybuilders use. Topical steroids are corticosteroids, synthetic relatives of cortisol, and bodybuilders use anabolic steroids, which are relatives of testosterone, so the two families share a chemical skeleton and almost nothing else. When this confusion appears in a comment, the clean answer is to name the two families.
A frightened buyer often believes that any steroid use leads to topical steroid withdrawal. The documented cases cluster in people who used moderate to potent steroids frequently for months or years, often on the face or genitals. Withdrawal reactions are real, and the British regulator acknowledged them in 2021 and has reported cases in children after as little as two months of continuous use. The frequency in ordinary, intermittent use is unknown and appears low.
The opposite myth, held by some doctors, is that topical steroid withdrawal is invented by the internet and is just eczema flaring. The British regulator’s 2021 assessment, the 2025 provisional criteria from the National Institutes of Health and a new diagnosis code approved in 2026 all point the other way, though many dermatologists still doubt it, and fifty-nine percent of seventy trainees and fellows in one 2025 survey did not regard it as a formal entity. The honest position is that it exists, it is poorly defined, and nobody knows how common it is.
The belief that steroid creams stop working over time is nearly universal in our corpus. A 2013 study of the evidence found no clinical trial showing that topical steroids lose effectiveness with continued use, and in one small study patients who had failed steroids all improved within a week when their use was supervised, which points to under-use as the usual explanation. The experience of it stopping working is real, and the most common cause is use that is too light or too brief.
Many people believe any steroid thins the skin permanently. Thinning is a real risk with repeated use of potent steroids on the same spot, especially on thin skin, and mild thinning usually reverses within weeks of stopping. Stretch marks from steroids are permanent. Low-potency steroids used appropriately on the body rarely cause visible thinning.
Patients are often told to use steroid cream sparingly, and many take that to mean a thin smear. The standard dose is the fingertip unit, about half a gram covering an area the size of two adult palms, and the thin smear is one of the quiet reasons a course fails and the patient concludes that the cream has stopped working.
Parents often fear that steroid creams on a baby will stunt growth or damage the child’s hormones. Effects on growth and the body’s hormone axis have been reported mainly with potent steroids used over large areas, under occlusion or for long periods, and low-potency steroids used as directed on small areas carry little of that risk. The fear is understandable, and it is the reason parents swing between using steroid in guilty bursts and withholding it, the reactive pattern described in episode five.
Some believe over-the-counter hydrocortisone is either harmless anywhere for any length of time, or so weak it is useless. One percent hydrocortisone is the mildest class and helps mild patches, though it rarely controls a moderate flare on the body. Long, frequent use on the face can still contribute to problems such as perioral dermatitis.
The belief that antihistamines stop eczema itch drives large sales of Benadryl and Zyrtec. Eczema itch is mostly driven by immune messengers acting on the nerves, and both American guidelines advise against antihistamines as eczema treatment, allowing sedating ones only for short-term help with sleep.
A belief common in the withdrawal community is that the skin becomes addicted to moisturiser. No good evidence supports a moisturiser addiction, and the Cochrane analysis of trials found that moisturisers reduce flares and the amount of steroid needed. Some people report doing better on less product during withdrawal, and that experience is real for them, though it has not been tested in trials.
Many parents believe that moisturising a newborn every day prevents eczema. Two large trials, BEEP and PreventADALL, found that it does not, and BEEP found a small rise in skin infections. Moisturiser treats and stabilises eczema once it exists.
Bleach baths sound dangerous to many sufferers. A dilute bleach bath uses about half a cup of household bleach in a full tub, roughly the concentration of a swimming pool, and the allergy guideline suggests it as an add-on for moderate to severe eczema, with some evidence that plain water baths help almost as much.
The belief that Protopic and Elidel cause cancer comes from the boxed warning added in 2006. That warning was based on animal studies and rare case reports, and long-term monitoring of children has not shown a clear increase in cancer. The warning is still printed on the box, and Phoilex’s villain inventory counted six hundred and twenty-three mentions of these drugs.
Many believe Dupixent is a steroid or a broad immune suppressant. It is a targeted antibody that blocks one receptor for two immune messengers, it needs no routine blood tests, and its main side effects are eye inflammation and facial redness. The opposite myth, that biologics cure eczema, is also common, and they control the disease while they are taken; many people describe it returning after stopping.
The broadest myth in the natural market is that natural means safe. Essential oils, tea tree oil and apple cider vinegar can irritate or burn broken skin, and plants from the daisy family, including chamomile, calendula and arnica, are known causes of allergic contact dermatitis in sensitised people. A commenter under one of our ads asked whether the gel contained tea tree oil because hidden botanicals had burned her before.
The belief that tallow, coconut oil or castor oil heals eczema is behind some of the biggest sellers in the category, including a tallow balm with more than six hundred and fifty thousand units sold on TikTok Shop. None of these has an eczema trial of any size. They are fatty occlusive moisturisers, and coconut oil reduced staph in one small trial, so they plausibly help dry skin the way any good occlusive does.
Shower filter sellers argue that hard water causes eczema. Some studies link hard water areas with more childhood eczema, and the SOFT trial, published in 2011, found that installing a water softener in the homes of three hundred and thirty-six children did not improve their eczema.
The belief that vitamin D supplements cure eczema is widespread, and our most-replayed video research found sufferers rewinding to the moment a creator credits vitamin D. Some trials, including one in Mongolian children with winter-worsening eczema, found benefit from supplements, and others found none. Vitamin D is a reasonable thing for a deficient person to take, and the evidence for it as an eczema treatment is mixed.
Many people believe sunlight cures eczema, and our comments include people who credit summer or tanning beds. Ultraviolet light is a real eczema treatment when given as medical phototherapy, and the sun helps many people, while heat and sweat make some people worse. Tanning beds carry skin cancer risk that dermatologists will not accept as a trade.
The belief that a cure exists and doctors are hiding it runs through many of our comments, in lines about big pharma and doctors trained only in pharmaceutical relief. There is no hidden cure. The newer drugs are a real advance and are expensive, and the system around them, with step therapy and short appointments, leaves many people feeling abandoned, which is the grievance underneath the conspiracy.
The last myth on the list is that scratching is a habit that can be stopped by willpower. The itch is driven by immune messengers acting on sensitised nerves, people scratch in their sleep without knowing it, and the useful advice is to reduce the itch and protect the skin, with short nails, cotton gloves at night for children, cooling and a treatment that calms the inflammation.
Most of these myths contain a true observation wrapped in a wrong explanation. The diet believer noticed that her skin changed when she changed her life. The steroid believer noticed that the patch returned when the cream stopped. The detox believer noticed that her skin reflects how she feels. When you answer a myth, start by agreeing with the observation, then give the better explanation, then give her something to check on her own skin. Episode eight turns to the buyers themselves, in their own words.
This episode is about the people who actually pay, described as precisely as our data allows, and heard in their own words. Every quotation in this episode is a real sufferer or buyer quote from Phoilex’s research files or from comments left on our own ads, and each one is marked with where it came from. Treat these lines as material for understanding, never as copy, because the brand rule is that a buyer’s line appears in an ad only inside a rating card with the buyer’s name. The episode moves from who buys, to the doorways and the lives behind them, to their emotional states, to what they have been burned by, and finally to their language, beat by beat.
Start with the hardest number we have, the age breakdown of the Phoilex ad account over the ninety days to late October 2026, recorded in YOUNG-LANE-PLAN-20261028.md. People aged sixty-five and over took fifty-two percent of the spend, thirty-seven thousand five hundred and fifty-eight dollars, and produced eight hundred and thirty-seven purchases at a cost of about forty-five dollars each, with a return of one point four two. The fifty-five to sixty-four group produced three hundred and six purchases at about fifty-five dollars. The forty-five to fifty-four group produced one hundred and fifty at about sixty-four dollars. The thirty-five to forty-four group was the most expensive, seventy-eight purchases at about eighty-three dollars. People under thirty-five received only one point five percent of the spend, and the twenty-five to thirty-four group bought twenty times at about fifty-two dollars, too few to judge.
Two conclusions follow from these numbers. The first is that the older buyer is real and profitable, and the long story ads that Meta sends to her work. The second is that the younger buyer is untested more than unprofitable, because the creative, the donors and the delivery have all pointed at older people. The under-forty-five plan proposes a separate lane of short creator-style videos for her, with ad devices such as the timeline of what happens over a number of days, the rating of every cream she tried, and the this was me and this is me now reveal.
A second fact about who buys comes from the store’s page data in LEARNINGS.md. Over thirty days in early September, one hundred and twenty-six of five hundred and forty-one buyers, about twenty-three percent, bought inside the Facebook or Instagram in-app browser, and repeat buyers made up about twelve percent of orders. Most of the money comes from first purchases by people who clicked a story and bought on their phone.
Phoilex’s market map, MARKET-MAP.md, organises the market into eight doorways, each defined by a word she types or a problem she names first, and each counted in both the Reddit corpus and the Google and Amazon autocomplete pull.
The steroid doorway is the trunk, with five hundred and seventeen Reddit items and one thousand two hundred and ninety-eight autocomplete strings. Its typed phrases include steroid free eczema cream and eczema without steroids, and it carried fifteen thousand three hundred and fifty-two of roughly twenty thousand landing sessions in one September week, and its default reader is the lifelong sufferer.
The face and eyelid doorway has four hundred and ninety Reddit items and three hundred and nineteen autocomplete strings, with phrases such as eczema eyelid and eczema lips. Its villain is a steroid on the thinnest skin on the body, and its default reader is the hider, the woman for whom eczema is a verdict on how she looks.
The Dupixent and biologics doorway has three hundred and ninety-eight Reddit items, and its autocomplete includes Dupixent withdrawal, Dupixent for kids and Dupixent in pregnancy. Cost dominates it, with fifty-eight of the corpus’s one hundred and thirty-five cost items. Its sub-avatar is insured but scared, the woman who can get the injection and does not want to inject herself for skin.
The hands doorway has two hundred and fifty-one Reddit items, and its clearest life is the nurse who washes her hands forty times a shift; fifty-two of the sixty-six occupational contact items sit inside it.
The baby and child doorway has one hundred and twenty-nine Reddit items and the largest Amazon autocomplete count of any door, seventy-six strings, with three hundred and twenty-nine on Google, including eczema cream for baby and what can I put on my baby’s eczema. Its reader is the desperate parent, and on our account she is often a grandparent.
The topical steroid withdrawal doorway has one hundred and four Reddit items by a narrow count and three hundred and forty-four autocomplete strings. It differs from the steroid door by stance: the steroid door still uses the cream, and the withdrawal door has quit it.
The psoriasis doorway has forty-eight Reddit items and is mostly organic traffic to the brand’s blog, and the pregnancy doorway, with one hundred and twenty-four Google strings and only fifteen Reddit items, is unmined, though every prescription on the ladder carries a pregnancy warning and steroid-free is a literal fit.
Inside the steroid door, the map lists several lives: the flexural hider who keeps the crook of her elbow and the backs of her knees covered in summer, with ninety-one flexural items, the woman whose eczema came back in her late forties around menopause, with thirty-seven items, the scalp sufferer, and the teenager or the teenager’s parent.
Phoilex’s personas folder holds four deep cases built from the corpus, and our account data demands a fifth.
The lifelong sufferer, in personas/01-lifelong-sufferer.md, has had eczema since before she can remember, has out-read her dermatologists, and believes this is just who she is and she can only manage it. Her core emotion is the wish for peace in her own skin, and her open question is whether anything actually fixes this or she manages it forever.
The desperate parent, in personas/02-desperate-parent.md, is caught between the steroid she fears and nothing at all. Her core emotions are relief and redemption, and her guilt has a specific origin: she followed a doctor’s instructions and put a cream with a warning on it onto her baby.
The TSW warrior, in personas/03-tsw-warrior.md, quit steroids and is healing from what she experiences as an injury done to her. She is the hardest to sell to, sceptical of products and sometimes of moisturiser itself, and what she wants is control, reclamation and vindication.
The hider, in personas/04-the-hider.md, has milder but visible eczema, often younger, dating, and organised around concealment, sabotaged at night by scratching in her sleep. A Reddit post in her evidence, with forty-eight upvotes, records an ex-partner telling her she scratched in her sleep and how embarrassed she was.
The fifth persona, which the folder does not yet contain, is the older adult, sixty-five and over, who is most of our buyers. She may have had eczema for sixty years or for six. She has tried the most, spent the most, and often trusts doctors the least. She reads long stories. She also buys for others, and grandparents appear repeatedly in our own comments describing grandsons who scratch until they bleed.
The messaging matrix describes the dominant belief state as hopeless, confirmed by the corpus, and the emotional state as high and exhausted rather than merely dissatisfied. The steady background is fatigue from poor sleep, shame at visible sites and an oscillation between hope, when a new diet or a new drug appears, and despair, when it fails. The matrix names the deepest emotion in the desire ladder as freedom, specifically freedom from dependence on products and routines, and the emotion copy should start from as entrapment, the sense that every topical is something she will one day have to come off.
The emotional states also differ by doorway. The parent is frightened and guilty. The withdrawal warrior is angry and vindicated. The hider is ashamed and watchful. The lifelong sufferer is tired and resigned. The older adult is often sceptical and tired of being sold to, and in our comments she is the one asking whether the company is real.
The burn list is long. They have been burned by steroid creams that worked and then came back worse, by over-the-counter creams that did nothing, by moisturisers they believe made them dependent, by doctors who spent five minutes and printed a prescription, by elimination diets that changed nothing, by supplements, by Dupixent when they stopped it, by allergy tests that led them to cut foods for no reason, by insurers who refused the expensive drugs, and by direct-response ads. Competitor buyers add their own burns: Gladskin’s one-star ratings on Trustpilot repeated five times that the product made the skin worse, and one complained that the company would not disclose what its key ingredient actually was.
What follows are their own words, grouped by the beat of the story they tell. Every line is a quotation from a sufferer or buyer, with its source.
On the night, a YouTube commenter in our comment bank wrote, “i wake up around 1-2 am every night since i’ve had it constantly itching and not being able to go back to sleep until about 4-5,” and a commenter on our own ad listed the cost of ten years as “itch, sores, bloody sheets, and mental anguish.” A Reddit poster in our bank wrote that “My bedsheets often looked like a crime scene.” Another commenter on our own ad wrote of her grandson, “He scratches at night in his sleep.”
On the itch itself, a Reddit poster in our bank wrote, “It’s the bone deep, fully under the skin itch that has me rolling on my bed trying not to claw the skin off my legs,” and a YouTube commenter in the same bank wrote, “I actually would love for my legs to be amputated, just so I can finally sleep.”
On the steroid arc, the clearest single statement of the valley in the whole corpus is a YouTube comment in our bank that reads, “Steroid cream would clear it up completely but then as soon as I stopped the cream it would come back. Being that you can’t use the steroid cream long term I would wait until I couldn’t bare the burning, itching and scaling of it before using it again.” A commenter on our own ad wrote, “I was prescribed clobetasol ointment for my eczema, but the doctor told me to use it for only two weeks and then stop, because continued use could cause my skin to thin.” Another commenter on our ads wrote, “I’m embarrassed cause I’m gone thru so many of this big tubs of steroid cream.”
On having tried everything, a commenter on our own ad wrote, “I have literally spent over $100k on Dr’s, clinics, snake oils and medications,” and another wrote, “I have spent so much money on over the counter stuff that I can open up my own drug store.” A YouTube commenter in our bank wrote, “I had a dermatologist tell me this would be life long. I almost lost hope.”
On shame and hiding, a YouTube commenter in our bank wrote, “I’m tired of hiding my skin I wanna wear shorts and sleeves shirts,” and another wrote, “I’ve been teased because of my eczema all over my arms. People used to say I was zombie skin.”
On the skin itself, the language clusters around reptiles, burns and raw wounds. TikTok creators in our bank described shedding skin “like a snake” and having “crocodile skin,” and one wrote, “It looked like I was burned. And it felt like this rash just kept eating me.”
On scepticism toward us, a commenter on our own ad wrote, “I am also suffering. The bottom line? Definitely not another cream or a miracle probiotic.” Another wrote, “Is anyone really there at Phoilex? I’ve sent questions to your posts here on Facebook and also on the company website Comment Page, and I never get a reply.” A third wrote that the story ads were “very similarly worded, just changing the person, the relative, and maybe the situation.”
On the win, the dream they describe is forgetting their skin. A Reddit poster in our bank wrote, “The biggest change… is that I never think about my skin. It sounds weird, but that’s such a gift.” Another wrote, “I’m writing this as I wake up for the first time in months from a full night of sleep.” A Gladskin buyer on Trustpilot wrote, “I feel like myself again!” And in one of the long recovery videos, the young woman whose mother had to feed her said she cried tears of happiness because she had not dreamt for so long.
If you keep only ten phrases from this market in your head, keep these, because they recur across every bank Phoilex has collected. The first is that it comes back worse when I stop, and the second is that the steroid only works while I’m using it. The third is the declaration that she has tried everything, and the fourth is the line that it only manages it and never cures the root cause. The fifth describes the itch as bone deep, and the sixth is the night scene of bloody sheets and scratching in my sleep. The seventh is the question of whether something will make my skin worse, which is the most common objection in the corpus. The eighth is the refusal of not another cream, which our own commenters wrote almost word for word. The ninth is being tired of hiding, of long sleeves in summer and jumpers worn in the heat. And the tenth, the language of the win, is I never think about my skin anymore.
The last lesson of this episode is about absence. The say-this, not-that vocabulary file in the Phoilex offer folder, written after a clinical ad was caught, lists the words sufferers almost never use for themselves: ceramide, barrier, lipids, trigger, resilient, emollient, inflammation. They describe their skin as raw, cracked, weeping, flaking, red and angry, and they speak of what sets it off where a doctor would say trigger. They speak of the seal on my skin or what keeps the water in, if they talk about it at all. The word flare is theirs, used constantly, with a warning from the severe end of the market, who distinguish constant raw skin from skin that comes and goes. And the word calm, which marketers love, appears in their mouths when they want something, rarely when they describe a result. Episode nine turns from the buyers to the competitors who are selling to them.
Eugene Schwartz, in Breakthrough Advertising, described how a market grows more sophisticated as it hears more claims. In a fresh market, a simple promise works. As competitors repeat it, the promise has to grow bigger. Once bigger promises stop working, the winning move is a new mechanism, a new explanation of why the problem exists and why this product solves it. In the most exhausted markets, the winning move is identification, an ad that makes the reader feel recognised before it promises anything. Phoilex’s brief places eczema at stage four to five, the late end of that scale, and the evidence in this episode supports that reading. The episode maps who sells what, which claims are worn out, and which angles are still open.
The biggest sellers by volume run no story at all. Third-party estimates from ASINsight, collected in Phoilex’s stage zero research file of 27 October 2026, put CeraVe Moisturizing Cream at around sixty thousand units a month on Amazon, with more than one hundred and forty thousand ratings. Aquaphor Healing Ointment and La Roche-Posay’s Cicaplast Balm each sit around the same level. Benadryl’s anti-itch gel sells forty to fifty thousand units a month, and Cortizone-10, which is hydrocortisone and therefore a steroid, sells twenty to fifty thousand per listing. Aveeno’s Baby Eczema Therapy and Eucerin’s Eczema Relief each sell around ten thousand. A hypochlorous acid spray called Magic Molecule sells around twenty thousand.
These brands sell on the pharmacy’s argument: barrier repair, colloidal oatmeal, ceramides, and the phrase dermatologist recommended. They carry no villain, they make no story, and they win on shelf presence, price and trust. The stage zero file makes an important observation: Phoilex’s second philosophy, the ceramide and barrier argument, is their argument. Any brand that leads with barrier repair is competing with a fifteen-dollar tub of CeraVe that the buyer already owns.
This is the layer that matters most for Phoilex’s ads, because these sellers advertise a pitch, and a pitch that has run for years with real money behind it is evidence of what this buyer responds to.
Terra Lotus sells a tallow balm with raw honey and has sold more than six hundred and fifty-nine thousand units on TikTok Shop with more than fifty-six thousand ratings at four point six stars, plus around twenty thousand units a month on Amazon. Its pitch is mostly anti-ageing, younger, softer skin from one natural jar, with eczema mentioned as safe for eczema-prone skin, and its villain is synthetic moisturisers and chemicals. One of its hooks, with nine thousand seven hundred and thirty engagements, invites the reader whose bathroom counter is full of creams that did not deliver to try this one next.
Emuaid sells EMUAIDMAX, an ointment of emu oil, silver and ceramide three, at about forty-six dollars for two ounces. Its top eczema ad ran for six hundred and nine days, from October 2024 to July 2026, and gathered more than one hundred and twenty-eight thousand engagements, making it the single biggest eczema ad Phoilex’s research found. Its headline asked why eczema itch keeps coming back, and its body opened on people who still suffer despite countless trips to the dermatologist. Its villain is bacteria on the skin that drive the itch, with a related ad claiming it eliminates ninety-nine point nine nine percent of itch-causing bacteria. Emuaid is the closest product to Phoilex’s gel, an emu oil and ceramide topical sold for eczema patches.
Based Supplies sells a tallow and honey balm with a founder story about making it for their son’s sensitive skin. Its thirty most engaged ads summed to more than six hundred thousand engagements, and its longest ran eight hundred and five days. Its biggest hook, at seventy-seven thousand engagements, said most bathroom counters look like a chemistry lab, with dozens of products and zero results. Its eczema landing page tells parents that a child’s skin is being attacked by the very creams meant to help it.
Smiles And Joys sells a herbal cream for eczema and psoriasis and is the longest-running seller in the category, with ads seen since August 2021, more than one thousand six hundred days. It ran thirty-five active ads on its brand page and twenty-eight more on two pages styled as an eczema and psoriasis blog. Its pitch is the plainest form of the steroid villain: a traditional herbal cream that treats eczema without steroid creams and expensive dermatologists, with a first-person story advertorial about years of frustration with modern medicine and the hidden dangers of steroid creams, and the brand claims seven hundred thousand buyers.
Marin Skincare sells a cream built on marine glycoproteins, with ads since 2023 and a top ad of more than twenty-one thousand engagements headlined steroid-free, powered by glycoproteins. One ad quotes a buyer saying her eczema is gone and the cream works better than her prescription steroid, and another claims it is clinically proven to work as well as or better than topical steroids without the side effects.
Sven’s Island sells a manuka honey cream and ointment through a skin quiz and subscriptions, with five free gifts on subscription and a sixty-day guarantee. Its ads run under several pages, including a doctor page and a founder page, and its villains are steroid creams that stop working or make things worse, and staph bacteria.
On TikTok Shop, a group of low-priced herbal creams from Chinese suppliers sells in large volume with no written argument at all, such as RoyceDerm at fifty-four thousand units and SanNuo at fifty-three thousand. Lopeie’s whipped tallow balm has sold one hundred and fifty-three thousand units at sixteen dollars. Hearth and Homestead’s tallow balm sells ten to twenty thousand units a month on Amazon and ranks in the top ten for eczema cream searches. Tubby Todd’s ointment leads the baby niche.
Gladskin, a microbiome cream built on an engineered enzyme that targets staph, sells at about fifty-nine dollars and holds a Trustpilot score of three out of five across one hundred and twenty-one ratings. Phoilex mined forty-one of them. Its one-star ratings repeat that it made the skin worse, and one attacks the company for not disclosing what its key ingredient actually is, which is the transparency opening Phoilex’s brief identified early.
Some of the biggest eczema advertisers sell no cream. Eskiin’s filtered showerhead gathered more than seventy-five thousand engagements on its eczema ads by blaming the water, and Tubo’s bath filter ran an ad for five hundred and forty-one days. Cosi Care sells a gentle scratcher. These sellers own the same buyer, and they confirm that a circumstance villain, the water in the shower, can sell well even with weak evidence, since the SOFT trial found water softeners did not help children’s eczema.
The drops compete with a different set, studied in liverty/research/07-tof-inside-out-study-20261105.md. Skinesa, which claims more than one hundred and fifty thousand buyers and has advertised since 2021, runs mostly video, thirty-five of its top forty ads, with its biggest at nearly forty thousand engagements over seven hundred and twenty-six days, built on the claim that gut bacteria are causing the skin rash. Nourri runs a similar video-led approach with the line that creams only work on the surface while its product goes deeper. Codex sells a children’s supplement around a missing amino acid, L-histidine. Noticed claims thirty-seven thousand buyers in about six months on the line clear your eczema from the inside.
The winning inside-out videos share a shape: thirty to ninety seconds, one hundred to two hundred and fifty spoken words, the product named in the first ten to fifteen seconds, one idea, a mild villain in which the cream is blamed only for treating the surface, one trial number, and a ninety-day guarantee. Phoilex’s drops, by contrast, spent ninety-seven percent of their budget on long native story ads that named the product three quarters of the way down.
Price is part of sophistication, because this buyer has been anchored low. On TikTok Shop, Lopeie’s tallow balm sells at about sixteen dollars and Terra Lotus at about twenty-six, and the Chinese herbal creams sell at twenty to forty. Emuaid’s two-ounce ointment lists at about forty-six dollars, Gladskin at about fifty-nine, and Sven’s Island at about sixty dollars one-time or forty-eight on subscription. Phoilex’s gel sits at forty-two dollars a tube, with two tubes at seventy-nine and three at one hundred and twelve, after a price test in August 2026 in which a fifty-nine-dollar ladder lost.
The most revealing price anchor comes from the buyer’s own attention. In Phoilex’s most-replayed research, the single highest-attention moment in a YouTube video with one and a half million views is a woman saying castor oil cost her about seven dollars, and close by, in another video, a supplement described as twenty dollars a pound on Amazon. Right next to the castor oil line, the same creator says she had spent a great deal on doctors and none of it worked. She is burned on spend and anchored at seven dollars at the same moment. The MARKET-NOW file concludes that a forty-two-dollar gel cannot win on price, and has to win by not being another thing that failed.
Across these sellers, the stage zero file identifies the pitches that keep recurring. The first is a natural cream that works without the steroid, with the steroid cream and the prescribing doctor as villain, a named natural hero ingredient, a switching crowd and a first-person story; it has run continuously since 2021 and it is philosophy one in plain form. The second is that the itch keeps coming back because of bacteria, run by Emuaid and Sven’s Island, which is absent from Phoilex’s philosophies and would need a true ingredient basis before Phoilex could borrow it. The third is that the skin recognises a natural fat and the shelf of chemical products is the villain, which holds the largest unit volume of any direct-response topical, mostly sold as anti-ageing. The fourth is that the cause is inside, usually the gut. The fifth is the barrier argument, which sells enormously on a shelf and weakly in a feed; the one direct-response seller found running it on eczema, Strawberry, peaked at about eleven hundred engagements on that angle while its keratosis pilaris ads reached fifteen thousand.
Several claims are now so common that this buyer discounts them on sight. Steroid-free is table stakes; our recovery corpus records a woman who was given steroid-free prescription creams that worked fine as well and did not address the root cause, and the phrase is an Amazon category with its own autocomplete tail. Natural is worn, and so is root cause, which our sufferer-language study found is half seller-talk in the TikTok set, heavy among creators selling gut protocols. Naming the itch-scratch cycle is worn. Claims of being clinically proven as good as steroids are common and unverifiable to her. Big numbers of happy buyers are everywhere. The long native story with a dramatic death has become recognisable as a format; a commenter on our own ad wrote that the stories were very similarly worded, just changing the person, the relative and the situation, and others called them AI-written.
Phoilex’s ad results, collected in LEARNINGS.md, add direct evidence about sophistication. The most striking finding is that the image carried more of the result than the words. The same body, a story about a husband who died of sepsis from his broken skin, ran under two images: a newspaper clipping returned one point five two, and a photo of a fridge emptied into a bin returned point seven one, on identical text. The lesson the team drew was that documentary artefacts such as clippings, charts, labels and letters work better than lifestyle photos for this market, because a skeptical reader trusts a document more than a scene. The dairypoison story, a dermatologist’s account built around a food villain, returned two point zero five, the best long-form body at the time, which confirms that the diet belief makes a strong opener. A dermatology nurse confession template, ported from another market, got a click rate a third of the account average and returned point three. A listicle bridge page sent two hundred and thirty-five visitors to the product and produced zero adds to cart. And short offer ads such as a half-price static performed well only because they were harvesting warm buyers created by the long stories.
Given all that, here are the angles that remain open, ranked by how well they fit the valley and the aha from episodes five and six.
The first open angle is the same-spot comeback named precisely. No competitor in the stage zero research leads with the fact that the flare returns in the same place, why it does, and what to do on the good days. It matches the most corroborated story in the corpus, it explains the valley without blaming the buyer, and it sets up a spot treatment as the answer.
The second is the disambiguation question, whether the flare in front of her is her eczema or her cream. Phoilex’s suggest-mining file ranked it as the strongest untested asset, because it is her own search and its resolution is a mechanism.
The third is the strength creep, the moment a doctor moves her up a class of steroid, drawn from the Jada Jones story in the New York Post. Phoilex’s own drops research found that a body built on clobetasol, the top rung, was the only drops story near break-even in its window. Many women in the valley have just been moved up a strength and feel the fear without having words for it.
The fourth is the discipline of the spot treatment: the one gentle thing applied to the worst patches only, kept when everything else is put down. It is agreed by both the subtraction crowd and the product-crediting crowd in our corpus, and no competitor owns it.
The fifth is the itch that antihistamines cannot touch, a real prediction error with three hundred and seventy corpus mentions and no competitor using it.
The sixth is the older adult’s eczema, which every competitor ignores in favour of babies, young women and anti-ageing. Our own account’s buyers are mostly over sixty-five, and the fact that eczema rises again after fifty, and that older skin thins more easily under potent steroids, is both true and almost never said to them directly.
The seventh is radical transparency. Gladskin’s buyers attacked it for hiding its active, our own commenters asked to see the full ingredient list and asked about tea tree oil, and Phoilex can name every ingredient and explain what each one is for.
The eighth is format. The inside-out sellers win with short videos, and the under-forty-five buyer lives on TikTok Shop, where tallow balms sell hundreds of thousands of units through creator videos. Phoilex has barely tested video in either product.
The last open angle is pregnancy, a doorway with one hundred and twenty-four Google strings that nobody serves, where every prescription on the ladder carries a warning. It needs a claims check before any ad, but it is uncontested ground.
This buyer has heard steroid-free, natural, root cause and clinically proven for years, and she has bought many of them. A louder version of any of those claims will not move her. What can move her is an explanation of her own experience that she has never heard and can check, such as why the flare returns in the same spot, together with a way of using the product that fits what the people who got better actually did, and a brand that shows her everything and answers her questions. Episode ten turns to Phoilex itself, to what it is, what it can truthfully claim, and where its risks lie.
The last episode turns the whole course onto Phoilex itself. You now know the biology, the treatments, the journey, the valley, the aha, the myths, the buyers and the competitors, which means you can look at this brand the way a sharp dermatologist, a sceptical buyer and a regulator would each look at it. This episode covers where the brand came from, what is in each product and what each ingredient can honestly do, which claims are true and safe, which are risky, and where the gaps are. Everything here comes from Phoilex’s brief, its FAQ, the Liverty fact bank and the outside literature from earlier episodes.
Phoilex was founded by Sarina Pilaroscia, its chief executive, who has had eczema all her life. The origin story in the brand’s own materials is her father, who had severe psoriasis, went through failed clinical trials and decades of steroid dependence, and described his flares as a constant sunburn that never went away. The brand reports that he went from three flares a week to one every few months. Sarina is the founder and is not a dermatologist, and the fact bank is explicit that she should never be described as one. The brand’s published philosophy, on its FAQ page, is an inside-out approach inspired by the techniques of native ancestors, aimed at the root of skin issues instead of masking symptoms, with a botanical blend it calls the Phyto-Active Blend in every product.
The Active ReLeaf Spot Gel comes in a two-fluid-ounce, sixty-millilitre tube. After a price test that ended on 26 August 2026, the standing ladder is forty-two dollars for one tube, seventy-nine for two and one hundred and twelve for three, each with a struck compare-at price exactly double, so the half-price claim on this ladder is honest. The fifty-nine-dollar ladder lost the test and is retired. One-time orders ship free from seventy-five dollars and subscriptions ship free at any amount. After purchase, buyers see an offer of three extra tubes at seventy-nine dollars, a single extra tube at twenty-seven if they decline, and the Liverty drops at thirty-nine. All paid traffic goes to one page, phoilex.com/pages/active-releaf.
There is no guarantee. The store’s real policy is seven days on unopened products, and Kalp ruled in August 2026 that no guarantee of any kind should be advertised, not even the seven-day return, because naming a weak policy raises the idea of risk and then answers it badly. Several older ad bodies carried a ninety-day money-back sentence the store did not honour, and they were flagged.
The full ingredient list, in the brief’s canonical facts, tells a more interesting story than the marketing names do, and it is worth understanding line by line.
The strongest element is the lipid system. The gel contains five ceramides, listed as ceramide AG, AP, NG, NP and EOP, together with cholesterol and stearic acid, a free fatty acid. That trio of ceramides, cholesterol and fatty acid is the physiological lipid mixture that barrier researchers recommend, and ceramide EOP is the long-chain ceramide that eczema skin is particularly short on. In plain terms, the gel contains the same three families of fat that make up the skin’s own barrier, which is a genuine and defensible point of difference against plain moisturisers, even though, as episode three noted, ceramide products have not been proven to beat good ordinary moisturisers in trials.
The second element is a set of water-binding ingredients: glycerin, urea, panthenol, butylene glycol and propanediol. Urea is a proven moisturising ingredient that also softens thick, scaly skin, and at higher strengths it stings broken skin, which may be one reason the brand’s FAQ says the gel should not go on open or weeping skin.
The third element is oils: grape seed, emu oil, sunflower seed, sea buckthorn, tamanu, jojoba esters, squalene and a medium-chain triglyceride. Sunflower oil has some evidence for supporting the barrier. Emu oil is an animal fat, which matters for any vegan claim across the brand; the drops carry a hundred-percent-vegan badge, and the gel, with emu oil, cannot.
The fourth element is the soothing botanicals: bisabolol, which comes from chamomile, Scutellaria baicalensis root, also called Chinese skullcap and a source of baicalin, plus calendula, arnica, birch bark, mullein, nettle, shiitake extract, aloe and lemon extract. Bisabolol and baicalin have laboratory and small clinical evidence for calming skin. Calendula and arnica, along with chamomile, belong to the daisy family, which is a known source of allergic contact dermatitis in sensitised people, so a small minority of eczema sufferers could react to them.
The fifth element is vitamin D. The ingredient list includes cholecalciferol, which is vitamin D3, and 7-dehydrocholesterol, the skin’s own precursor to vitamin D3. The brand calls this a Triple Vitamin D3 Complex, and the brief notes that the wording three forms of vitamin D3 is the approved phrase; which ingredient counts as the third form should be confirmed with the client. These are cosmetic forms of vitamin D, which differ from the prescription vitamin D analogues such as calcipotriol that dermatologists use for psoriasis. Vitamin D does influence the skin’s immune cells and its natural antimicrobial peptides, and low vitamin D is associated with worse eczema, but topical cholecalciferol has little direct evidence as an eczema treatment. The brief flags the vitamin D claim as open for exactly this reason.
The formula also includes dimethyl isosorbide, which helps other ingredients penetrate, and a gentle preservative pair of benzyl alcohol and dehydroacetic acid, and it is free of the long list the brand publishes, including parabens, phthalates, silicones, petroleum, mineral oil, synthetic fragrance and phenoxyethanol.
Two items in the brand’s marketing do not match the ingredient list, and both matter. The first is colloidal oatmeal. The brand’s eight named ingredient blocks include it, and Kalp confirmed on 28 September 2026 that the gel contains it, but the full ingredient list in the brief omits it, and the gap matters well beyond labelling. Colloidal oatmeal is the active ingredient in the FDA’s over-the-counter skin protectant rules, and that status is what allows a product to legally say it temporarily relieves itching and irritation due to eczema. A product that wants to make that claim needs colloidal oatmeal declared as an active ingredient on a drug facts label at the required strength. If the gel’s label does not carry it that way, every eczema claim on the brand’s pages sits on cosmetic ground, where claims to treat a disease are not allowed.
The second is the hemp-balanced extract, named as one of the eight blocks, with no hemp or cannabis entry in the ingredient list. That needs reconciling before it appears in any ad, both for truth and because hemp and CBD carry their own advertising restrictions.
On solid ground, the gel is steroid-free, fragrance-free in the sense of no synthetic fragrance, free of the published list of excluded ingredients, made with ceramides, cholesterol and fatty acids in the family of the skin’s own barrier fats, made with named soothing botanicals, and dermatologist-tested. It holds a National Psoriasis Foundation Seal of Recognition, verified on the foundation’s site, which reflects testing for non-irritation and non-sensitisation; the foundation states that it does not endorse specific treatments, so the approved wording is recognised by the National Psoriasis Foundation, never approved or proven by it. It won a 2025 SHAPE Skin Award, judged by editors, and a 2025 BeautyMatter award, and it is stocked in Ulta stores. The New York Post’s July 2025 feature on topical steroid withdrawal named Phoilex and the gel, and the brand’s press list includes outlets such as Women’s Health, Yahoo, AOL and MSN.
The efficacy numbers need careful handling. The brand’s pages and the New York Post cite ninety-three percent of users feeling itch relief for four to twelve hours and seventy-four percent seeing fewer flare-ups after eight weeks. The Liverty fact bank records that these figures come from a small trial of nineteen people on the brand’s clinical page, and Phoilex does not hold the raw trial data. One page once claimed ninety-one percent fewer flare-ups, a number the Post never printed. The brief records Kalp’s ruling that the press-cited numbers ship and that he owns the compliance line on them. As a student of this market, you should know that a nineteen-person, eight-week, uncontrolled result is weak evidence, and that a dermatologist reading the ad will know it too.
Several claims in the brief’s authority stack carry real risk. The adopted headline describing the gel as the number one dermatologist-recommended steroid-free spot gel is a superlative with no survey behind it in our files. The peer figures of five hundred dermatologists and forty thousand flare-prone women are described in the brief as superstructure figures, and their basis is not documented. The authority figure Dr. Sarah Holloway, described as Stanford-trained, is invented, and the brief itself marks her for vetting before scaling. The brand has real experts available instead: Dr. Margarita Lolis, a board-certified dermatologist, and Dr. John Papastergiou, a pharmacist associated with the University of Toronto, are named advisors on the drops page. In a market where commenters already ask whether the company is real, an invented doctor who is discovered would cost far more trust than a real advisor with a smaller title.
The client’s own compliance table, assets/claims-substitutions.csv with seventy-two banned and approved pairs, sets the rules for new copy. It replaces anti-inflammatory with wording about lessening the appearance of temporary redness and replaces barrier repair with enhance. The brief also bans telling anyone to stop a prescription, scaremongering frightened parents, implying that steroids are pharmacologically like opioids, and fabricated press.
Liverty Dynamic Drops come in a thirty-millilitre bottle of lemon-tasting oil, one millilitre under the tongue daily, at forty-eight dollars. The ingredient list, in order, is MCT oil, milk thistle extract, turmeric extract, stevia, nettle leaf extract, lemon balm extract, chaga extract, licorice extract, lemon peel oil, cannabidiol and vitamin E. The front label reads one thousand milligrams full-spectrum CBD and supports healthy liver function. The drops have four ratings on the store, all five stars, and one of them is unusually strong evidence of its kind: a woman whose scalp cleared, flared again when she forgot the drops on a week-long trip, and calmed again when she restarted.
The honest mechanism, covered in episode six, is that glycyrrhizin from licorice slows the enzyme that inactivates cortisol, keeping the body’s own cortisol active for longer, shown in human skin in a 1990 Lancet paper, and that a pharmaceutical glycyrrhizin preparation taken with a mild steroid cream beat the cream alone in a 2020 trial of one hundred and ninety-nine adults. Lemon balm has a small sleep trial, and stress is the trigger sufferers name most. No trial of the drops themselves exists, the herb doses are not published, and the liver story is true for psoriasis but not for eczema.
The risks are significant. The CBD on the label means the drops fall under Meta’s and Google’s bans on advertising ingestible CBD, and the brief notes this from September 2026; current practice keeps the word out of all copy while the bottle can appear on screen, which leaves the account exposed if a policy checker at the platform reads the label. Full-spectrum CBD can carry traces of THC, and the PDP research found forty-one autocomplete strings asking about drug tests and THC. Licorice in high doses can raise blood pressure and lower potassium, CBD can interact with drugs such as blood thinners through the liver’s processing enzymes, and milk thistle can affect people with ragweed allergy. These are not reasons to stop selling the drops, and they are reasons to keep claims modest and the FAQ honest, especially for the over-sixty-five buyer who is more likely to take other medications.
Commercially, the drops have not yet found their form. Over ninety days they returned about point nine against a break-even of one point five, with almost all the money spent on long story ads borrowed from the gel. The best small results came from ads that led with the drops themselves, and the category’s proven sellers win with short videos naming one inside cause.
The brand is real and has traction, and the account is not yet profitable at the level the team needs. In early September 2026, the blended return across all channels was one point one one against a break-even of one point five, and Meta was over-claiming purchases by a factor of about two point seven against the store’s own records, though its relative ranking of ads was trustworthy. A finding from August shows about five point seven percent of purchases recorded at zero dollars, never fully explained. The average order on the forty-two-dollar ladder was about sixty-one dollars, which shows buyers climbing to the two-tube rung.
The research folder identifies gaps that cost sales and trust, and they are the practical end of this course. The product page does not tell people with specific variants, such as dyshidrotic, nummular, seborrheic or contact dermatitis, or psoriasis, whether the gel suits them, though one hundred and sixty-six questions in the research ask exactly that. The page says nothing about pregnancy or breastfeeding, and it does not explain the emu oil or whether it clogs pores. It tells people not to use the gel on open or weeping skin only at the bottom of a FAQ row, which disqualifies the most desperate buyers without offering them anything. The packaging itself misspells the Phyto-Active Blend as Phtyo. And the most visible trust gap sits under the ads: commenters asked repeatedly whether anyone at Phoilex was real, said their questions on Facebook and the website went unanswered, and one asked plainly whether the gel contained tea tree oil. Answering those comments, in a real person’s voice, would do more for this sceptical market than any new claim.
Here is the summary you can carry into any meeting. Phoilex sells a steroid-free spot gel with a real barrier-lipid system, real soothing botanicals and real third-party recognition, into a market stuck in the same-spot comeback and frightened of the cream that works. Its strongest truthful position is the one gentle thing she keeps on the spots that keep coming back, used on the good days as well as the bad, alongside whatever her doctor has her on. Its weakest points are an evidence base of nineteen people, an invented doctor, a superlative nobody has measured, an ingredient list that does not yet declare the oatmeal its eczema claims depend on, and a second product that carries CBD into ad platforms that ban it. Fix those, and the brand’s story matches what the science and the people who got better both say.
These are ranked by priority for Kalp, with the most useful first, and each entry says which episode of the course it deepens so the EPUBs can be digested in the right order.
Number one is The Remarkable Life of the Skin by Monty Lyman, published in 2019, a doctor’s readable tour of the barrier, the skin’s microbes, itch and the psychology of visible skin disease, which deepens episodes one and two and is the fastest way to think like a dermatologist without a textbook.
Number two is Management of Atopic Dermatitis: Methods and Challenges, edited by Eric Fortson, Steven Feldman and Lindsay Strowd and published by Springer in 2017, a clinician’s book that covers treatment, adherence and steroid fear from the group behind the tachyphylaxis work, and it deepens episodes three and five.
Number three is Fitzpatrick’s Dermatology, ninth edition, edited by Sewon Kang and colleagues and published in 2019, the reference textbook to read selectively for the atopic dermatitis, itch and topical steroid chapters, which deepens episodes two and three.
Number four is Itch: Mechanisms and Treatment, edited by Earl Carstens and Tasuku Akiyama and published by CRC Press in 2014, the science of why eczema itch is mostly not histamine, which deepens episode two and the second aha in episode six.
Number five is The Wounded Storyteller by Arthur Frank, published in 1995, the sociologist’s map of how chronically ill people tell their stories as restitution, chaos or quest, which explains the TSW journey videos and deepens episodes four and eight.
Number six is The Invisible Kingdom by Meghan O’Rourke, published in 2022, a memoir and investigation of chronic illness that doctors struggle to see or believe, which explains the anger and distrust in the withdrawal community and deepens episodes four and five.
Number seven is Breakthrough Advertising by Eugene Schwartz, published in 1966, the source of the market sophistication stages used in episode nine and the clearest framework for why a new mechanism beats a louder claim in this market.
Number eight is Clean: The New Science of Skin by James Hamblin, published in 2020, on the skin microbiome and the product-heavy routines that the tallow and natural sellers attack, which deepens episodes seven and nine.
Number nine is Beyond Soap by Sandy Skotnicki with Christopher Shulgan, published in 2018, a dermatologist’s case against over-washing and product overload, useful for understanding the empty-counter dream in our recovery corpus, and it deepens episodes seven and eight.
Number ten is Allergic: Our Irritated Bodies in a Changing World by Theresa MacPhail, published in 2023, on why atopic disease is rising and how immunologists think about it, which deepens episodes one and two and the atopic march.
Number eleven is This Isn’t Eczema by Claire Oxenham, self-published in May 2021, an illustrated guide to topical steroid withdrawal written from inside the community after fifteen months of her own withdrawal, which gives the TSW vocabulary first-hand and deepens episodes four and eight.
Number twelve is Curing My Incurable Eczema by Cara Ward, released in December 2017, a TSW memoir that shows how the steroid arc is told by the people who live it, which deepens episodes four, five and eight.
Number thirteen is The Illness Narratives by Arthur Kleinman, published in 1988, the psychiatrist and anthropologist’s classic on how patients make meaning from chronic illness, which deepens episode eight and the emotional states of the buyers.
Number fourteen is The Eczema Diet by Karen Fischer, first published in Australia in 2008 with later editions, the best-known diet-based eczema book, read to understand the inward turn of the valley and the beliefs behind the diet villain, which deepens episodes five and seven.
Number fifteen is An Epidemic of Absence by Moises Velasquez-Manoff, published in 2012, on the hygiene and old-friends hypotheses behind rising allergic disease, which deepens episodes two and seven.
Number sixteen is Skin: A Natural History by Nina Jablonski, published in 2006, an anthropologist’s account of skin and its pigment, useful background for eczema on darker skin, which deepens episode two.
Number seventeen is Bad Pharma by Ben Goldacre, published in 2012, on how drug trials are designed and reported, which helps judge every clinically proven claim in the category, including our own nineteen-person trial, and deepens episodes nine and ten.
Sources are listed by episode, one per line, internal Phoilex files first and outside literature after, so the episodes themselves can be read aloud without citations.
Source: Phoilex internal, offers/phoilex/YOUNG-LANE-PLAN-20261028.md, Meta account age breakdown for the ninety days to late October 2026, eight hundred and thirty-seven of one thousand three hundred and ninety-one purchases from people aged sixty-five and over
Source: Phoilex internal, offers/phoilex/research/eczema-voc-20261028/STUDY.md, the October 2026 sufferer-language study across four banks
Source: Phoilex internal, offers/phoilex/MARKET-MAP.md, the market map of doorways, sub-avatars and objections, 15 September 2026
Source: Phoilex internal, offers/phoilex/brief.md, offer classification, canonical facts and the three philosophies
Source: Phoilex internal, offers/phoilex/research/stage0-proven-sellers-gel-20261027.md, competitor sales evidence
Source: Phoilex internal, offers/phoilex/research/own-ad-comments.jsonl, three hundred and eighty-six comments on Phoilex ads from August to September 2026
Source: National Eczema Association, Eczema Stats, https://nationaleczema.org/research/eczema-facts/
Source: HealthDay summary of the 2021 and 2024 National Health Interview Survey analysis of atopic dermatitis prevalence, https://www.healthday.com/dermatology-special/2021-to-2024-saw-increase-in-prevalence-of-atopic-dermatitis
Source: Lee and colleagues, A systematic review and meta-analysis of the prevalence and phenotype of adult-onset atopic dermatitis, Journal of the American Academy of Dermatology, published online 2018, pooled adult-onset share of twenty-six point one percent
Source: MDedge, Managing atopic dermatitis in older adults, a common, unique challenge, on the bimodal incidence in United Kingdom primary care data, https://mdedge.com/content/managing-atopic-dermatitis-older-adults-common-unique-challenge
Source: Dupixent list price, manufacturer cost page, four thousand one hundred and ninety-three dollars and three cents per carton as of 2 January 2026, https://www.dupixent.com/FR-FAQitems/getting-dupixent-and-costs/What-is-the-cost-of-DUPIXENT
Source: Palmer and colleagues, Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis, Nature Genetics, volume 38, 2006, pages 441 to 446
Source: Oetjen and colleagues, Sensory neurons co-opt classical immune signaling pathways to mediate chronic itch, Cell, volume 171, 2017, https://pmc.ncbi.nlm.nih.gov/articles/PMC5658016
Source: Kong and colleagues, Temporal shifts in the skin microbiome associated with atopic dermatitis disease flares and treatment, Genome Research, volume 22, 2012, pages 850 to 859, https://genome.cshlp.org/content/22/5/850
Source: The circadian rhythm of itching among two hundred and forty-one adults with atopic dermatitis, a cross-sectional study, Acta Dermato-Venereologica, https://medicaljournalssweden.se/actadv/article/view/35427
Source: Sleep disturbance in atopic dermatitis, pooled prevalence ranges in children and adults, https://pmc.ncbi.nlm.nih.gov/articles/PMC9026738/
Source: National Eczema Society, Eczema Unmasked survey 2020, stress named as the biggest trigger by fifty-seven percent of women and forty-one percent of men, https://www.eczema.org.uk/information-and-advice/triggers-for-eczema/stress-and-eczema/
Source: Fudan University, A sympathetic-eosinophil axis orchestrates psychological stress to exacerbate skin inflammation, Science, 19 March 2026, doi 10.1126/science.adv5974, work in mice
Source: Du Toit and colleagues, Randomized trial of peanut consumption in infants at risk for peanut allergy, the LEAP trial, New England Journal of Medicine, volume 372, 2015
Source: Chansky and colleagues on atopic dermatitis in skin of colour, erythema under-recognition and follicular morphology, https://pmc.ncbi.nlm.nih.gov/articles/PMC5843478
Source: Dupilumab in elderly patients with atopic dermatitis, a systematic review and meta-analysis, noting no randomised trial limited to people aged sixty and over, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12839263/
Source: Phoilex internal, offers/phoilex/research/eczema-voc-20261028/STUDY.md and C-comments-reviews.md, for the bone-deep itch and bloody sheets lines
Source: Sidbury and colleagues, Guidelines of care for the management of atopic dermatitis in adults with topical therapies, Journal of the American Academy of Dermatology, volume 89, 2023, doi 10.1016/j.jaad.2022.12.029, with the 2025 focused update by Davis and Sidbury
Source: Chu and colleagues, Atopic dermatitis (eczema) guidelines, 2023 American Academy of Allergy, Asthma and Immunology and American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters, Annals of Allergy, Asthma and Immunology, published online 17 December 2023
Source: van Zuuren and colleagues, Emollients and moisturisers for eczema, Cochrane Database of Systematic Reviews, 2017
Source: Chalmers and colleagues, the BEEP randomised controlled trial of daily emollient in infancy, The Lancet, 2020, and the five-year follow-up, https://www.medicinesresources.nhs.uk/daily-emollient-during-infancy-for-prevention-of-eczema-the-beep-randomised-controlled-trial.html
Source: Skjerven and colleagues, the PreventADALL trial of skin emollient and early food introduction, The Lancet, 2020
Source: Berth-Jones and colleagues, Twice weekly fluticasone propionate added to emollient maintenance treatment to reduce risk of relapse in atopic dermatitis, British Medical Journal, 2003, https://www.aafp.org/afp/2004/0201/p658
Source: Schmitt and colleagues, Efficacy and tolerability of proactive treatment with topical corticosteroids and calcineurin inhibitors for atopic eczema, British Journal of Dermatology, 2011, https://pubmed.ncbi.nlm.nih.gov/20819086/
Source: Haapasaari and colleagues, collagen synthesis suppression by topical corticosteroids in healthy volunteers, Acta Dermato-Venereologica, volume 75, 1995
Source: Egeberg and colleagues, Association of potent and very potent topical corticosteroids with osteoporosis and major osteoporotic fractures, JAMA Dermatology, volume 157, 2021
Source: Li, Yin and Antaya, Topical corticosteroid phobia in atopic dermatitis, a systematic review, JAMA Dermatology, volume 153, 2017, pages 1036 to 1042, https://jamanetwork.com/journals/jamadermatology/fullarticle/2643740
Source: FDA approvals for roflumilast cream, lebrikizumab, nemolizumab and tapinarof in 2024, ruxolitinib cream for ages two and up in September 2025 and delgocitinib for chronic hand eczema in July 2025, https://www.contemporarypediatrics.com/view/key-atopic-dermatitis-approvals-are-changing-the-treatment-landscape and https://ajmc.com/view/recent-fda-approvals-expand-dermatology-options-for-patients-with-skin-of-color
Source: Oykhman and colleagues, Dietary elimination for the treatment of atopic dermatitis, a systematic review and meta-analysis, Journal of Allergy and Clinical Immunology in Practice, volume 10, 2022, doi 10.1016/j.jaip.2022.06.044
Source: European Academy of Allergy and Clinical Immunology task force, a systematic review and meta-analysis of nutritional and dietary interventions in children with atopic dermatitis, 2024, https://eaaci.org/guidelines-position-papers/a-systematic-review-and-meta-analysis-of-nutritional-and-dietary-interventions-in-randomized-controlled-trials-for-skin-symptoms-in-children-with-atopic-dermatitis-and-without-food-allergy-an-eaaci-t/
Source: Camargo and colleagues, randomised trial of vitamin D supplementation for winter-related atopic dermatitis in Mongolian children, Journal of Allergy and Clinical Immunology, 2014
Source: Saeedi and colleagues, The treatment of atopic dermatitis with licorice gel, Journal of Dermatological Treatment, 2003, https://pubmed.ncbi.nlm.nih.gov/14522625/
Source: Manuka honey pilot in atopic dermatitis, https://dermatologytimes.com/view/manuka-honey-tested-ad-treatment
Source: Phoilex internal, offers/phoilex/VILLAIN-INVENTORY-20260825.md, corpus counts for moisturising, calcineurin inhibitors, JAK pills, antihistamines and bleach baths
Source: Phoilex internal, offers/phoilex/personas/01-lifelong-sufferer.md, 02-desperate-parent.md, 03-tsw-warrior.md and 04-the-hider.md
Source: Phoilex internal, offers/phoilex/personas/MARKET-NOW.md, section D on the five TSW journeys and the sixth buyer-intent journey, with records in copy-hub/arcs
Source: Phoilex internal, offers/phoilex/liverty/NYPOST-READ-20261105.md and the New York Post feature of 2 July 2025, https://nypost.com/2025/07/02/health/scary-condition-that-traps-you-in-your-own-half-alive-corpse/
Source: Kligman and Frosch, Steroid addiction, International Journal of Dermatology, 1979
Source: Rapaport and Lebwohl, Corticosteroid addiction and withdrawal in the atopic, the red burning skin syndrome, Clinics in Dermatology, 2003
Source: Hajar and colleagues, A systematic review of topical corticosteroid withdrawal (steroid addiction) in patients with atopic dermatitis and other dermatoses, Journal of the American Academy of Dermatology, volume 72, 2015
Source: MHRA, Topical steroid withdrawal reactions, a review of the evidence, September 2021, https://www.gov.uk/government/publications/topical-steroid-withdrawal-reactions-a-review-of-the-evidence/topical-steroid-withdrawal-reactions-a-review-of-the-evidence
Source: Pharmaceutical Journal on MHRA potency labelling and two hundred and sixty-seven reports, May 2024, https://pharmaceutical-journal.com/article/news/potency-warning-labels-for-topical-steroids-to-be-introduced-following-reports-of-adverse-reactions
Source: Shobnam, Myles and colleagues, provisional diagnostic criteria for topical steroid withdrawal and NAD plus findings, Journal of Investigative Dermatology, 2025, doi 10.1016/j.jid.2024.11.026, https://www.niaid.nih.gov/news-events/topical-steroid-withdrawal-diagnostic-criteria-defined-nih-researchers
Source: Dermatology Times on the new diagnosis code for topical steroid withdrawal and the ITSAN registry, https://www.dermatologytimes.com/view/the-cutaneous-connection-new-icd-10-code-offers-validation-for-patients-with-topical-steroid-withdrawal
Source: Australasian Journal of Dermatology, 2025 survey of seventy dermatology fellows and trainees, fifty-nine percent not regarding TSW as a formal clinical entity, as reported in the search summary for this course
Source: Barta and colleagues, topical corticosteroid exposure and cumulative effects in patients with eczema, Annals of Allergy, Asthma and Immunology, published online September 2022, https://www.ajmc.com/view/prolonged-corticosteroid-exposure-associated-with-adverse-effects-for-patients-with-atopic-dermatitis
Source: Healio on poor reliability of YouTube videos about topical steroid withdrawal, December 2023, https://cm.healio.com/news/dermatology/20231201/youtube-content-on-topical-steroid-withdrawal-exhibits-poor-reliability-quality
Source: Kim, Chao, Simpson and Silverberg, Persistence of atopic dermatitis, a systematic review and meta-analysis, Journal of the American Academy of Dermatology, volume 75, 2016
Source: Phoilex internal, offers/phoilex/research/eczema-voc-20261028/STUDY.md, section 1 on the steroid arc present in all four banks
Source: Phoilex internal, offers/phoilex/personas/MARKET-NOW.md, belief ranking and the two hundred and twenty-three and eight hundred and six upvote lines
Source: Phoilex internal, offers/phoilex/MARKET-MAP.md, section 4 objection counts
Source: Phoilex internal, offers/phoilex/research/suggest-mining-20260812.md, the fear cluster and the disambiguation searches
Source: Phoilex internal, offers/phoilex/liverty/FACT-BANK.md, row 4.16 on the eighty-five comeback suggestions
Source: Phoilex internal, offers/phoilex/research/own-ad-comments.jsonl, theme counts computed for this course
Source: Phoilex internal, offers/phoilex/messaging-matrix.md, belief state and objection analysis
Source: Taheri, Cantrell and Feldman, Tachyphylaxis to topical glucocorticoids, what is the evidence, Dermatology Online Journal, volume 19, 2013, https://escholarship.org/uc/doj/19/7
Source: Lax and colleagues, Strategies for using topical corticosteroids in children and adults with eczema, Cochrane, 2022, summarised at https://www.aafp.org/afp/2023/0200/cochrane-corticosteroids-eczema
Source: Phoilex internal, offers/phoilex/philosophy-1-steroid-addiction.md and philosophy-1-deepened.md, including the internal honesty note
Source: Phoilex internal, offers/phoilex/philosophy-2-broken-wall.md and eczema-research-study.md
Source: Phoilex internal, offers/phoilex/STATE-20261028.md, the twelveyears ad at four thousand two hundred and thirty-five dollars and a return of one point five two
Source: Phoilex internal, offers/phoilex/liverty/research/07-tof-inside-out-study-20261105.md, drops spend by format and the return of about point nine
Source: Slominski and colleagues, the cutaneous hypothalamic-pituitary-adrenal axis homolog papers of 2007, 2011, 2012 and 2015, as listed in philosophy-1-deepened.md
Source: Teelucksingh and colleagues, Potentiation of hydrocortisone activity in skin by glycyrrhetinic acid, The Lancet, volume 335, 1990, pages 1060 to 1063, https://www.ncbi.nlm.nih.gov/pubmed/1970371
Source: Xu and colleagues, compound glycyrrhizin capsules with mometasone cream in chronic eczema, Evidence-Based Complementary and Alternative Medicine, 2020, https://pubmed.ncbi.nlm.nih.gov/32308712/
Source: Thomas and colleagues, the SOFT trial of ion-exchange water softeners for eczema in children, PLoS Medicine, 2011
Source: Eczema and non-alcoholic fatty liver disease rates in moderate to severe eczema compared with controls, https://pmc.ncbi.nlm.nih.gov/articles/PMC10531586
Source: Phoilex internal, offers/phoilex/research/PDP-QUESTION-GAPS-20260812.md, variant and safety questions
Source: Phoilex internal, offers/phoilex/research/QUESTIONS-20260812.md, one thousand eight hundred and forty-four unique questions from autocomplete and YouTube comments
Source: Phoilex internal, offers/phoilex/LEARNINGS.md, in-app browser share and repeat orders
Source: Phoilex internal, offers/phoilex/research/eczema-voc-20261028/A-tiktok-sufferers.md, B-longform-tsw.md, C-comments-reviews.md and D-reddit.md, the verbatim banks quoted in this episode
Source: Phoilex internal, offers/phoilex/CUSTOMER-VOCABULARY.md, the say-this, not-that map
Source: Phoilex internal, offers/phoilex/research/reviews-trustpilot/DIGEST.md, forty-one Gladskin ratings
Source: Phoilex internal, offers/phoilex/research/stage0-proven-sellers-gel-20261027.md, sales and engagement figures for every seller named
Source: Phoilex internal, offers/phoilex/liverty/research/07-tof-inside-out-study-20261105.md and 06-stage0-proven-sellers-20261027.md, inside-out sellers
Source: Phoilex internal, offers/phoilex/LEARNINGS.md, ad results by body and image
Source: Phoilex internal, offers/phoilex/personas/MARKET-NOW.md, section C on the most-replayed moments and price anchors
Source: Eugene Schwartz, Breakthrough Advertising, 1966
Source: Phoilex internal, offers/phoilex/brief.md, section 2 canonical facts, the full ingredient list, the price ladder, the guarantee ruling, the authority stack and the real press section
Source: Phoilex internal, offers/phoilex/research/FAQ-PHOILEX-SITE.md, the brand’s published FAQ
Source: Phoilex internal, offers/phoilex/liverty/FACT-BANK.md, rows 1.11 to 1.24 on the drops label, ingredients, ratings and the trial attribution of the gel’s numbers
Source: Phoilex internal, offers/phoilex/research/PDP-QUESTION-GAPS-20260812.md, the gaps on variants, pregnancy, emu oil, CBD and weeping skin
Source: National Psoriasis Foundation Seal of Recognition listings for the gel and the drops, https://www.psoriasis.org/seal-of-recognition/phoilex/liverty-dynamic-drops/
Source: United States Code of Federal Regulations, title 21 part 347, skin protectant drug products for over-the-counter human use, colloidal oatmeal as a monograph active ingredient